PYRIDINYL AMIDES AND IMIDES FOR USE AS FUNGICIDES

Abstract: Compounds of Formula (I), their N-oxides and agriculturally suitable salts are disclosed which are useful as fungicides formula (I), (II) wherein A is a substituted pyridinyl ring; B is a substituted pyridinyl ring; W is C=L or SOn is O or S; R<1> and R<2> are each independently H; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C3-C6 cycloalkyl, each optionally substituted; R<3> is H; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C3-C6 cycloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 alkylaminocarbonyl or C3-C8 dialkylaminocarbonyl; R<4> is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C3-C6 cycloalkyl, each optionally substituted; X is O or S; and n is 1 or 2; provided that when W is C=O and R<1>, R<2> and R<3> are H; then B is other than 4-trifluoromethyl-3-pyridinyl, 2-chloro-4-pyridinyl and 2,6-dihalo-4-pyridinyl.Also disclosed are compositions containing the compounds of Formula (I) and a method for controlling plant diseases caused by fungal plant pathogens that involves applying an effective amount of a compound of Formula (I).

Description: TITLE PYRIDINYL AMIDES AND IMIDES FOR USE AS FUNGICIDES BACKGROUND OF THE INVENTION This invention relates to certain pyridinyl amides and imides, their N-oxides, agriculturally suitable salts and compositions, and methods of their use as fungicides. The control of plant diseases caused by fungal plant pathogens is extremely important in achieving high crop efficiency. Plant disease damage to ornamental, vegetable, field, cereal, and fruit crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. Many products are commercially available for these purposes, but the need continues for new compounds, which are more effective, less costly, less toxic, environmentally safer or have different modes of action. WO 99/42447 discloses certain benzamides of formula i as fungicides wherein, among others, R is H, alkyl or acyl; R 2 is H or alkyl; and L is -(C=0)-, -SQ 2 - or -(C=S)- SUMMARY OF THE INVENTION This invention pertains to compounds of Formula I or Formula II including all geometric and stereoisomers, N-oxides, and agriculturally suitable salts thereof: wherein A is a substituted pyridinyl ring; B is a substituted pyridinyl ring; W is C-L or SO n ; L is O or S; R 1 and R 2 are each independently H; or Cj-Cg alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C3-C6 cycloalkyl, each optionally substituted; R 3 is H; or C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 6 cycloalkyl, C 2 -C 6 alkylcarbonyl, C 2 -Cg alkoxycarbonyl, C -C6 alkylamrnocarbonyl or C3-C8 dialkylaminocarbonyl; R 4 is C^Cg alkyl, C 2 -Cg alkenyl, C 2 -C 6 alkynyl or C3~C 6 cycloalkyl, each optionally substituted; X is O or S; and n is 1 or 2; provided that when W is C=O and R 1 , R 2 and R 3 are H; then B is other than 4-trifluoromethyl-3 -pyridinyl, 2-chloro-4-pyridinyl and 2,6-dihalo-4-pyridinyl. This invention also relates to fungicidal compositions comprising fungicidally effective amounts of the compounds of the invention and at least one additional component selected from the group consisting of surfactants, solid diluents or liquid diluents and/or at least one other fungicide having a different mode of action. This invention also relates to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed or seedling, a fungicidally effective amount of the compounds of the invention (e.g., as a composition described herein). DETAILS OF THE INVENTION As noted above, A and B are each independently a substituted pyridinyl ring. The term "substituted" in connection with these A or B groups refers to groups that have at least one non-hydrogen substituent that does not extinguish the fungicidal activity. Examples of Formula I and Formula II incorporating said pyridinyl rings in which A is substituted with 1 to 4 R 5 , B is substituted with 1 to 4 R 6 include the rings illustrated in Exhibit 1 wherein m and p are independently integers from 1 to 4. Note that the attachment point between (R 5 ) m and A and (R 6 ) p and B is illustrated as floating, and (R 5 ) m and (R 6 ) p can be attached to any available carbon atom of the pyridinyl rings. Exhibit 1 I-l 1-2 1-3 1-4 1-5 1-6 1-7 1-9 Examples of R 5 when attached to A and R 6 when attached to B include: R 5 andR 6 are each independently C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, CN, CO 2 H, CONH 2 , NO 2 , hydroxy, -C 4 alkoxy, -C 4 haloalkoxy, C 1 -C 4 alkylthio, -C 4 alkylsulfinyl, C 1 -C4 alkylsulfonyl, -C4 haloalkylthio, -C4 haloalkylsulfinyl, -C 4 haloalkylsulfonyl, C1-C 4 alkoxycarbonyl, C j -04 alkylamino, C 2 -Cg dialkylamino, C 3 -Cg cycloalkylamino, C 2 -C6 alkylcarbonyl, C 2 -Cg alkoxycarbonyl, C -C alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl, C 3 -Cg trialkylsilyl; or R 5 and R 6 are each independently phenyl, benzyl or phenoxy, each optionally substituted with C 1 -C4 alkyl, C 2 -C4 alkenyl, C 2 -C 4 alkynyl, C -C6 cycloalkyl, C r C haloalkyl, C 2 -C 4 haloalkenyl, C 2 -C haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, CN, NO 2 , C j -C- 4 alkoxy, C r C 4 haloalkoxy, C r C 4 alkylthio, C1-C 4 alkylsulfinyl, -C4 alkylsulfonyl -C4 alkoxycarbonyl, C1-C4 alkylamino, C 2 -C 8 dialkylamino, C 3 -Cg cycloalkylamino, C 3 -C6 (alkyl)cyclo alkylamino, C 2 -C 4 alkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl or C 3 -Cg trialkylsilyl. Other R 5 and R 6 groups will be evident to one of ordinary skill. For example, each R 5 and/or R 6 can be NH 2 , NHCO(C r C 4 alkyl) or NHCO(C r C 4 haloalkyl); or each R 5 and/or R 6 can be phenyl, benzyl or phenoxy, each substituted with C 5 -Cg trialklylsilylalkynyl. Of note are compounds of Formula I wherein R 5 and R 6 are each independently -Cg alkyl, C 2 -C6 alkenyl, C 2 -C 6 alkynyl, C 3 -C6 cycloalkyl, Cι-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, CN, CO 2 H, CONH 2 , NO 2 , hydroxy, C r C 4 alkoxy, -C 4 haloalkoxy, C 1 -C 4 alkylthio, C1-C 4 alkylsulfinyl, -C 4 alkylsulfonyl, C1-C 4 haloalkylthio, C1-C 4 haloalkylsulfinyl, C 1 -C4 haloalkylsulfonyl, Cχ-0 4 alkoxycarbonyl, C 1 -C4 alkylamino, C 2 -Cg dialkylamino, C 3 -Cg cycloalkylamino, C 2 -C 6 alkylcarbonyl, C 2 -Cg alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl, C 3 -Cg trialkylsilyl; or R 5 and R 6 are each independently phenyl, benzyl or phenoxy, each optionally substituted with C1-C4 alkyl, C 2 -C 4 alkenyl, C 2 -C4 alkynyl, C 3 -C 6 cycloalkyl, C1-C 4 haloalkyl, C 2 -C 4 haloalkenyl, C 2 -C haloalkynyl, C 3 -C6 halocycloalkyl, halogen, CN, NO 2 , C 1 -C4 alkoxy, C r C 4 haloalkoxy, C r C 4 alkylthio, C1-C 4 alkylsulfinyl, C1-C4 alkylsulfonyl CJ-C4 alkoxycarbonyl, C1-C4 alkylamino, C -C § dialkylamino, C 3 -C6 cycloalkylamino, C 3 -C6 (alkyl)cycloalkylamrno, C 2 -C 4 alkylcarbonyl, C -Cg alkoxycarbonyl, C 2 -C 6 alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl, C 5 -Cg trialklylsilylalkynyl or C 3 -C 6 trialkylsilyl. As noted above, R 1 and R 2 are each independently H; or Cj-Cg alkyl, C -C 6 alkenyl, C 2 -C 6 alkynyl or C 3 -C 6 cycloalkyl, each optionally substituted; andR4 is C^-Cg alkyl, C 2 - Cg alkenyl, C 2 -C 6 alkynyl or C 3 -C6 cycloalkyl, each optionally substituted. The term "optionally substituted" in connection with these R 1 , R 2 and R 4 groups refers to groups which are unsubstituted or have at least one non-hydrogen substituent that does not extinguish the fungicidal activity possessed by the unsubstituted analog. Examples of optionally substituted R 1 , R 2 and R 4 groups are those that are optionally substituted with one or more substituents selected from the group consisting of halogen, CN, NO 2 , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, 0^4 alkylsulfinyl, -C4 alkylsulfonyl, C 2 -C 4 alkoxycarbonyl, C1-C4 alkylamino, C 2 -Cg dialkylamino and C -C cycloalkylamino. Although these substituents are hsted in the examples above, it is noted that they do not need to be present since they are optional substituents. Examples of N-oxides of Formula I or Formula II are illustrated as I- 10 through 1-16 and as 11-10 through 11-16, respectively, in Exhibit 2, wherein R 1 , R 2 , R3, R , R5 ? R6^ W, X, m and p are as defined above. Exhibit 2 1-10 Ml 1-12 1-13 1-14 1-15 1-16 In the above recitations, the term "alkyl", used either alone or in compound words such as "alkylthio" or "haloalkyl" includes straight-chain or branched alkyl, such as, methyl, ethyl, 77-propyl, /-propyl, or the different butyl, pentyl or hexyl isomers. The term "1-2 alkyl" indicates that one or two of the available positions for that substituent may be alkyl which are independently selected. "Alkenyl" includes straight chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. "Alkenyl" also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. "Alkynyl" includes straight chain or branched alkynes such as ethynyl, 1-propynyl, 2-ρropynyl and the different butynyl, pentynyl and hexynyl isomers. "Alkynyl" can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. "Alkoxy" includes, for example, methoxy, ethoxy, n-propyloxy, isopropyloxy and the different butoxy, pentoxy andhexyloxy isomers. "Alkoxyalkyl" denotes alkoxy substitution on alkyl. Examples of "alkoxyalkyl" include CH 3 OCH 2 , CH 3 OCH 2 CH 2 , CH 3 CH 2 OCH 2 , CH 3 CH 2 CH 2 CH 2 OCH 2 and CH 3 CH 2 OCH 2 CH 2 . "Alkoxyalkoxy" denotes alkoxy substitution on alkoxy. The term "Alkenyloxy" includes straight chain or branched alkenyloxy moieties. Examples of "alkenyloxy" include H^^CHC^O, (CH 3 ) 2 C=CHCH 2 O, (CH 3 )CH=CHCH 2 O, (CH 3 )CH=C(CH 3 )CH 2 O and CH 2 =CHCH 2 CH 2 O. "Alkynyloxy" includes straight chain or branched alkynyloxy moieties. Examples of "alkynyloxy" include HC≡CCH 2 O, CH 3 C≡CCH 2 O and CH 3 C≡CCH 2 CH 2 O. "Alkylthio" includes branched or straight chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers. "Alkylthioalkyl" denotes alkylthio substitution on alkyl. Examples of "alkylthioalkyl" include CH 3 SCH 2 , CH 3 SCH 2 CH 2 , CH 3 CH 2 SCH 2 , CH 3 CH 2 CH 2 CH 2 SCH 2 and CH 3 CH 2 SCH 2 CH 2 . "Alkylthioalkoxy" denotes alkylthio substitution on alkoxy. "Alkylsulfinyl" includes both enantiomers of an alkylsulfinyl group. Examples of "alkylsulfinyl" include CH 3 S(O), CH 3 CH 2 S(O), CH 3 CH 2 CH 2 S(O), (CH 3 ) 2 CHS(O) and the different butylsulfinyl, pentylsulfinyl and hexylsulfinyl isomers. Examples of "alkylsulfonyl" include CH 3 S(O) 2 , CH 3 CH 2 S(O) 2 , CH 3 CH 2 CH 2 S(O) 2 , (CH 3 ) 2 CHS(O) 2 and the different butylsulfonyl, pentylsulfonyl and hexylsulfonyl isomers. "Cyanoalkyl" denotes an alkyl group substituted with one cyano group. Examples of "cyanoalkyl" include NCCH 2 , NCCH 2 CH 2 and CH 3 CH(CN)CH 2 . "Alkylamino", "dialkylamino", "alkenylthio", "alkenylsulfinyl", "alkenylsulfonyl", "alkynylthio", "alkynylsulfinyl", "alkynylsulfonyl", and the like, are defined analogously to the above examples. "Cycloalkyl" includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The term "cycloalkoxy" includes the same groups linked through an oxygen atom such as cyclopentyloxy and cyclohexyloxy. The term "halogen", either alone or in compound words such as "haloalkyl", includes fluorine, chlorine, bromine or iodine. The term "1-2 halogen" indicates that one or two of the available positions for that substituent may be halogen which are independently selected. Further, when used in compound words such as "haloalkyl", said alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of "haloalkyl" include F 3 C, C1CH 2 , CF 3 CH 2 and CF 3 CC1 2 . The terms "haloalkenyl", "haloalkynyl", "haloalkoxy", "haloalkylthio", and the like, are defined analogously to the term "haloalkyl". Examples of "haloalkenyl" include (C1) 2 C=CHCH 2 and CF 3 CH 2 CH=CHCH 2 . Examples of "haloalkynyl" include HC≡CCHCl, CF 3 C≡C, CC1 3 C≡C and FCH 2 C≡CCH 2 . Examples of "haloalkoxy" include CF 3 O, CCl 3 CH 2 O, HCF 2 CH 2 CH 2 O and CF 3 CH 2 O. Examples of "haloalkylthio" include CC1 3 S, CF 3 S, CC1 3 CH 2 S and C1CH 2 CH 2 CH 2 S. Examples of "haloalkylsulfinyl" include CF 3 S(O), CCl 3 S(O), CF 3 CH 2 S(O) and CF 3 CF 2 S(O). Examples of "haloalkylsulfonyl" include CF 3 S(O) 2 , CCl 3 S(O) 2 , CF 3 CH 2 S(O) 2 and CF 3 CF 2 S(O) 2 . Examples of "haloalkoxyalkoxy" include CF 3 OCH 2 O, ClCH 2 CH 2 OCH 2 CH 2 O, Cl 3 CCH 2 OCH 2 O as well as branched alkyl derivatives. Examples of "alkylcarbonyl" include C(O)CH 3 , C(O)CH 2 CH 2 CH 3 and C(O)CH(CH 3 ) 2 . Examples of "alkoxycarbonyl" include CH 3 OC(=O), CH 3 CH 2 OC(=O), CH 3 CH 2 CH 2 OC(=O), (CH 3 ) 2 CHOC(=O) and the different butoxy- or pentoxycarbonyl isomers. One skilled in the art will appreciate that not all nitrogen containing heterocycles can form N-oxides since the nitrogen requires an available lone pair for oxidation to the oxide; one skilled in the art will recognize those nitrogen containing heterocycles which can form N-oxides. One skilled in the art will also recognize that tertiary amines can form N-oxides. Synthetic methods for the preparation of N-oxides of heterocycles and tertiary amines are very well known by one skilled in the art including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic and -chloroperbenzoic acid (MCPB A), hydrogen peroxide, alkyl hydroperoxides such as t-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethydioxirane. These methods for the preparation of N-oxides have been extensively described and reviewed in the literature, see for example: T. L. Gilchrist in Comprehensive Organic Synthesis, vol. 7, pp 748-750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik in Comprehensive Heterocyclic Chemistry, vol. 3, pp 18-20, A. J. Boulton and A. McKillop, Eds., Pergamon Press; M. R. Grimmett and B. R. T. Keene in Advances in Heterocyclic Chemistry, vol. 43, pp 149-161, A. R. Katritzky, Ed., Academic Press; M. Tisler andB. Stanovnik in Advances in Heterocyclic Chemistry, vol. 9, pp 285-291, A. R. Katritzky and A. J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G. Werstiuk in Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press. The total number of carbon atoms in a substituent group is indicated by the "Ci-C j " prefix where i and j are numbers from 1 to 8. For example, Cj-C 3 alkylsulfonyl designates methylsulfonyl through propylsulfonyl; C alkoxyalkyl designates CH 3 OCH 2 ; C 3 alkoxyalkyl designates, for example, CH 3 CH(OCH 3 ), CH 3 OCH 2 CH 2 or CH 3 CH 2 OCH 2 ; and C alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH 3 CH 2 CH 2 OCH 2 and CH 3 CH 2 OCH 2 CH 2 . When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents. Further, when the subscript indicates a range, e.g. (R)i_ j , then the number of substituents may be selected from the integers between i and j inclusive. When a group contains a substituent which can be hydrogen, for example R or R 2 then, when this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted. Compounds of this invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. Accordingly, the present invention comprises compounds selected from Formula I, N-oxides and agriculturally suitable salts thereof. The compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an optically active form. In particular, when R l and R 2 of Formula I and Formula II are different, then said formulas possess a chiral center at the carbon to which they are commonly bonded. This invention comprises racemic mixtures. In addition, this invention includes compounds that are enriched compared to the racemic mixture in an enantiomer of the formulas Included are the essentially pure enantiomers of Formula F and Formula IF. This invention also includes compounds that are enriched compared to the racemic mixture in an enantiomer of the formulas Included are the essentially pure enantiomers of Formula I' ' and Formula II". When enantiomerically enriched, one enantiomer is present in greater amounts that the other and the extent of enrichment can be defined by an expression of enantiomer excess("ee"), which is defined as 100(2x-l) where x is the mole fraction of the dominant enantiomer in the mixture, (e.g., an ee of 20% corresponds to a 60:40 ratio of enantiomers). The more active enantiomer with respect to the relative positions of R 1 , R 2 , A and the rest of the molecule bonded through nitrogen corresponds to the configuration of the enantiomer of 2,4-dichloro-N-[(lR)- l-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl]-3- pyridinecarboxamide that, when in a solution of CDC1 , rotates plane polarized light in the (+) or dextro direction (i.e. the predominant enantiomer of Compound 31 of Index Table B). Preferably the compositions of this invention have at least a 50 % enantiomeric excess; more preferably at least a 75 % enantiomeric excess; still more preferably at least a 90 % enantiomeric excess; and the most preferably at least a 94 % enantiomeric excess of the more active isomer. Of particular note are enantiomerically pure embodiments of the more active isomer. Compounds of Formula π can also exist as (E)- or (Z)-isomers , or as a mixture of (E)- and (Z)-isomers with respect to the C=Ν bond shown in the structure. This invention comprises mixtures of geometric isomers as well as the individual isomers. The salts of the compounds of the invention include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids. The salts of the compounds of the invention also include those formed with organic bases (e.g., pyridine, ammonia, or triethylamine) or inorganic bases (e.g., hydrides, hydroxides, or carbonates of sodium, potassium, hthium, calcium, magnesium or barium) when the compound contains an acidic group such as a carboxylic acid or phenol. Preferred compounds for reasons of better activity and/or ease of synthesis are: Preferred 1. Preferred are compounds of Formula I or Formula π wherein A is a pyridinyl ring substituted with from 1 to 4 R 5 ; B is a pyridinyl ring substituted with from 1 to 4 R 6 ; R l and R 2 are each independently H; or C^-Cg alkyl, C 2 -Cg alkenyl, C 2 -Cg alkynyl or C 3 -Cg cycloalkyl, each optionally substituted with one or more substituents selected from the group consisting of halogen, CN, NO 2 , hydroxy, C1-C 4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C 1 -C4 alkylsulfonyl, C 2 -C4 alkoxycarbonyl, C r C4 alkylamino, C 2 -C 8 dialkylamino and C 3 -C 6 cycloalkylamino; R is Ci-Cg alkyl, C 2 -C6 alkenyl, C 2 -Cg alkynyl or C 3 -C 6 cycloalkyl, each optionally substituted with one or more substituents selected from the group consisting of halogen, CN, NO 2 , hydroxy, C1-C 4 alkoxy, C1-C 4 alkylthio, γ- alkylsulfinyl, C1-C 4 alkylsulfonyl, C 2 -C 4 alkoxycarbonyl, C1-C 4 alkylamino, C 2 -Cg dialkylamino and C 3 -C 6 cycloalkylamino; and R 5 and R 6 are each independently -Cg alkyl, C 2 -Cg alkenyl, C 2 -Cg alkynyl, C 3 -C 6 cycloalkyl, C j -Cg haloalkyl, C 2 -C 6 haloalkenyl, C -Cg haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, CN, CO 2 H, CONH 2 , NO 2 , hydroxy, Cι-C 4 alkoxy, -C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 haloalkylthio, C1-C4 haloalkylsulfinyl, C -C4 haloalkylsulfonyl, C1-C 4 alkoxycarbonyl, C1-C 4 alkylamino, C 2 -Cg dialkylamino, C 3 -Cg cycloalkylamino, C 2 -Cg alkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 2 -C alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl, C 3 -Cg trialkylsilyl; or R 5 and R 6 are each independently phenyl, benzyl or phenoxy, each optionally substituted with C1-C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C4 alkynyl, C 3 -C6 cycloalkyl, C1-C4 haloalkyl, C 2 -C 4 haloalkenyl, C 2 -C haloalkynyl, C 3 -Cg halocycloalkyl, halogen, CN, NO 2 , C1-C4 alkoxy, C1-C4 haloalkoxy, C 1 -C4 alkylthio, 0^ 4 alkylsulfinyl, C 1 -C4 alkylsulfonyl C 1 -C 4 alkoxycarbonyl, C 1 -C 4 alkylamino, C 2 -Cg dialkylamino, C 3 -Cg cycloalkylamino, C 3 -Cg (alkyl)cycloalkylamino, C 2 -C 4 alkylcarbonyl, C 2 -C alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl or C 3 -Cg trialkylsilyl. e compounds of Preferred 1 wherein each R 5 is independently C j -Cg alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, Cj-Cg haloalkyl, C 2 -C6 haloalkenyl, C 2 -Cg haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, CN, CO 2 H, CONH 2 , NO 2 , hydroxy, -C 4 alkoxy, C 1 -C4 haloalkoxy, -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C4 alkylsulfonyl, C 1 -C 4 haloalkylthio, C1-C 4 haloalkylsulfinyl, C1-C4 haloalkylsulfonyl, C 1 -C4 alkoxycarbonyl, C 1 -C 4 alkylamino, C 2 -Cg dialkylamino, C 3 -C6 cycloalkylamino, C 2 -Cg alkylcarbonyl, C -Cg alkoxycarbonyl, C 2 -C 6 alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl, C 3 -Cg trialkylsilyl; provided that when A is 2-pyridinyl, then R 5 is other than C^ to Cg haloalkyl; and each R 6 is independently C^-Cg alkyl, C -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -Cg cycloalkyl, C j -Cg haloalkyl, C 2 -Cg haloalkenyl, C 2 -Cg haloalkynyl, C -C 6 halocycloalkyl, halogen, CN, CO 2 H, CONH 2 , NO 2 , hydroxy, C 1 -C4 alkoxy, C1-C4 haloalkoxy, C 1 -C4 alkylthio, C1-C4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, C 1 -C 4 haloalkylthio, C1-C4 haloalkylsulfinyl, C1-C 4 haloalkylsulfonyl, C 1 -C 4 alkoxycarbonyl, C1-C4 alkylamino, C 2 -Cg dialkylamino, C 3 -C 6 cycloalkylamino, C 2 -Cg alkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl, C 3 -C 6 trialkylsilyl; or R 5 and R 6 are each independently phenyl, benzyl or phenoxy, each optionally substituted with C1-C4 alkyl, C 2 -C4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 6 cycloalkyl, 0^4 haloalkyl, C 2 -C4 haloalkenyl, C 2 -C 4 haloalkynyl, C 3 -Cg halocycloalkyl, halogen, CN, NO 2 , -C4 alkoxy, C1-C 4 haloalkoxy, -C4 alkylthio, C 1 -C4 alkylsulfinyl, C 1 -C4 alkylsulfonyl C 1 -C4 alkoxycarbonyl, C 1 -C4 alkylamino, C 2 -Cg dialkylamino, C 3 -Cg cycloalkylamino, C 3 -C 6 (alkyl)cycloalkylamino, C 2 -C 4 alkylcarbonyl, C 2 -Cg alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl or C 3 -C5 trialkylsilyl. Preferred 2. Compounds of Preferred 1 of Formula I wherein W is C=O. Of note are compounds of Preferred 2 wherein A is a substituted 3-pyridinyl ring. Also of note are compounds of Preferred 2 wherein each R 5 is independently C j -Cg alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C^-Cg haloalkyl, C 2 -Cg haloalkenyl, C 2 -Cg haloalkynyl, C 3 -C6 halocycloalkyl, halogen, CN, CO 2 H, CONH 2 , NO 2 , hydroxy, C r C 4 alkoxy, C1-C 4 haloalkoxy, C1-C4 alkylthio, C1-C 4 alkylsulfinyl, C1-C 4 alkylsulfonyl, C 1 -C 4 haloalkylthio, C 1 -C4 haloalkylsulfinyl, C 1 -C4 haloalkylsulfonyl, C1-C 4 alkoxycarbonyl, C 1 -C4 alkylamino, C 2 -Cg dialkylamino, C 3 -Cg cycloalkylamino, C 2 -C alkylcarbonyl, C 2 -Cg alkoxycarbonyl, C -Cg alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl, C 3 -Cg trialkylsilyl; provided that when A is 2-pyridrnyl, then R 5 is other than C^ to Cg haloalkyl. Preferred 3. Compounds of Preferred 2 wherein A is a 2-pyridrnyl ring substituted with from 1 to 4 R 5 ; and B is substituted with from 1 to 4 R 6 , with at least one R 6 located in a position ortho to the link with W. Of note are compounds of Preferred 3 wherein R 5 is CI, Br, CH 3 , OCF , OCHF 2 , OCH 2 CF 3) OCF 2 CF 3 , OCF 2 CF 2 H, OCHFCF 3 , SCF 3 , SCHF 2 , SCH 2 CF 3 , SCF 2 CF 3 , SCF 2 CF 2 H, SCHFCF 3 , SOCF 3 , SOCHF 2 , SOCH 2 CF 3 , SOCF 2 CF 3 , SOCF 2 CF 2 H, SOCHFCF 3 , SO 2 CF 3 , SO 2 CHF 2 , SO 2 CH 2 CF 3 , SO 2 CF 2 CF 3 , SO 2 CF 2 CF 2 H or SO 2 CHFCF 3 . Also of note are compounds of Preferred 3 wherein B is either a 3-pyridinyl or 4-pyridinyl ring having an R 6 at each position ortho to the link with W (and optionally 1 to 2 additional R 6 ). Preferred 4. Compounds of Preferred 3 wherein B is either a 3-pyridinyl or 4-pyridinyl ring having an R 6 at each position ortho to the link with W, and optionally 1 to 2 additional R 6 and R 6 is either halogen or methyl. Preferred 5. Compounds of Preferred 4 wherein B is a 3-pyridinyl ring wherein one R 6 is CI and is located at the 2-position ortho to the link with W, another R 6 is selected from CI or methyl and is located at the 4-position ortho to the link with W and a third optional R 6 is methyl at the 6-position. Preferred 6. Compounds of Preferred 5 wherein A is 3-chloro-5-CF 3 -2-pyridinyl. Preferred 7. Compounds of Preferred 3, but especially Preferred 4, wherein R is H and R is CH 3 . Preferred 8. Compounds of Preferred 1 of Formula II wherein A is a 2-pyridinyl ring substituted with from 1 to 4 R 5 ; and B is substituted with from 1 to 4 R 6 , with at least one R 6 located in a position ortho to the link with the carbon that is bonded to both X and B. Preferred 9. Compounds of Preferred 5 wherein X is S . Preferred compounds of this invention include those of Preferred 1 through Preferred 9 wherein R l is H or CH , R 2 is H and (in Formula I) R 3 is H. Specifically preferred are the compounds selected from the group consisting of 2,4-DicMoro-N-[[3-chloro-5-(trifluorome yl)-2-pyridinyl]methyl]-3- pyridinecarboxamide, 2,4-Dic oro-N-[l-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl]-3- pyridinecarboxamide, 2,4-Dichloro-N-[[3-chloro-5-(trifluorome yl)-2-pyridmyl]methyl]-6-methyl-3- pyridinecarboxamide, and 2,4-DicUoro-N-[l-[3-chloro-5-( fluorome l)-2-pyridinyl]ethyl]-6-methyl-3- pyridinecarboxamide. Also specifically preferred are the compounds selected from the group consisting of 2,4-DicMoro-N-[(3,5-mcMoro-2-pyridinyl)methyl]-3-pvridinecarboxamide, 2,4-DicMoro-N-[l-(3,5-mcMoro-2-pyridmyl)e yl]-3-pyridrnecarboxamide, 2,4-Dichloro-N-[(3,5-dichloro-2-pyridinyl)methyl]-6-methyl-3- pyridinecarboxamide, 2,4-Dichloro-N-[ 1 -(3,5-dichloro-2-pyridinyl)ethyl]-6-methyl-3- pyridinecarboxamide, N-[(5-bromo-3-chloro-2-pyridmyl)me yl]-2,4-dichloro-3-pyriclinecarboxamide, N-[l-(5-bromo-3-chloro-2-pyridinyl)ethyl]-2,4-dichloro-3-pyridinecarboxamide, N-[(5-bromo-3-chloro-2-pyridinyl)methyl]-2,4-dichloro-6-methyl-3- pyridinecarboxamide, and N-[l-(5-bromo-3-chloro-2-pyridinyl)e t hyl]-2,4-dichloro-6-methyl-3- pyridinecarboxamide. This invention also relates to fungicidal compositions comprising fungicidally effective amounts of the compounds of the invention and at least one additional component selected from the group consisting of surfactants, solid diluents or liquid diluents. The preferred compositions of the present invention are those which comprise the above preferred compounds. This invention also relates to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed or seedling, a fungicidally effective amount of the compounds of the invention (e.g., as a composition described herein). The preferred methods of use are those involving the above- preferred compounds. The compounds of Formula I and Formula II can be prepared by one or more of the following methods and variations as described in Schemes 1-6. The definitions of A, B, L, W, Rl through R 6 , X and n in the compounds of Formulas 1-4 below are as defined above. Compounds of Formula la, lb and lc are subsets of Formula 1. Compounds of Formulae la, lb and Ic are subsets of the compounds of Formula I, and all substituents for Formulae la, lb and Ic are as defined above for Formula I. Compounds of Formula Ila are a subset of the compounds of Formula π, and all substituents for Formula Ila are as defined above for Formula II. The compounds of Formula I can be prepared as described below in Schemes 1-5. The compounds of Formula Ic and Ila can be prepared as described below in Scheme 6. The compounds of Formula la are prepared by treating amine salts of Formula 1 with an appropriate acid chloride in an inert solvent with two molar equivalents of a base (e.g. triethylamine or potassium carbonate) present. Suitable solvents are selected from the group consisting of ethers such as tetrahydro furan, drmethoxyethane, or diethyl ether; hydrocarbons such as toluene or benzene; and halocarbons such as dichloromethane or chloroform. Scheme 1 ι la Alternatively, compounds of Formula la can be synthesized by reacting the amine salts of Formula 1 with an appropriate carboxylic acid in the presence of an organic dehydrating reagent such as 1,3-d cyclohexylcarbocriimide (DCC) or l-[3-(Dimethylamino)propyl]-3- ethylcarbodiimide hydrochloride (EDC) as depicted in Scheme 2. Suitable solvents are selected from the group consisting of ethers such as tetrahydrofuran, dimethoxyethane, or diethyl ether; hydrocarbons such as toluene or benzene; and halocarbons such as dichloromethane or chloroform. Scheme 2 1 la Intermediate salt la, wherein A is 2-pyridyl bearing the indicated substituents and R 1 , R 2 , and R 3 are hydrogen, can be prepared by reacting the commercially available imine ester 5 shown in Scheme 3 with a 2,3-dichloro-pyridine substituted with R 5 (of Formula 4) in the presence of a strong base such as sodium hydride in a polar, aprotic solvent such as NN- dimethylformamide followed by heating in acidic medium in a procedure analogous to those found in WO99/42447. Compounds of Formula lb can be prepared by similar procedures in which the intermediate anion resulting from step 1 is treated with an alkylating agent such as methyl iodide prior to heating in an acidic medium. Of note are compounds wherein R 5 is CF 3 . la Compounds of Formula lc (wherein A is a substituted pyridinyl ring), bearing an aminomethyl group, can be synthesized from nitriles of Formula 2 (wherein A is a substituted pyridinyl ring) by reduction of the nitrile using lithium aluminum hydride in toluene to give the corresponding aminomethyl intermediates (Scheme 4). Scheme 4 LAH ,NH ^N PhMe lc A is a substituted pyridinyl ring Alternatively, compounds of Formula lc (compounds in which A is as defined above and Rl and R 2 are hydrogen) can be synthesized by reacting compounds of Formula 3 with ammonia in a protic solvent such as methanol to provide compounds of Formula 1 c. Compounds of Formula 1 c can also be prepared by reacting compounds of Formula 3 with a potassium salt of phthalimide followed by reaction with either aminoethanol or hydrazine in an alcohol solvent to provide the desired aminomethyl intermediates, Formula lc (Scheme 5). Scheme 5 LG is CI, Br, -OS0 2 Me, -OS0 2 -p-Tol Compounds of Formula Ila (compounds in wliich Rl, R 2 , A and B are as defined above and X is S) can be synthesized as outlined in Scheme 6. Amides of Formula lb (compounds of Formula I in which R 3 is H) shown below can be converted to thioamides of Formula Ic by contacting the amide with Lawesson's reagent or phosphorus pentasulfide in an appropriate solvent (for references, see March; J. Advanced Organic Chemistry, 4 th ed., pp. 893-4). The thioamide can then be alkylated using an appropriate alkylating reagent in the presence of a base such as potassium carbonate, sodium hydride or potassium hydroxide. Suitable solvents can include, but are not limited to, ethers such as tetrahydrofuran, dimethoxyethane, or diethyl ether; hydrocarbons such as toluene or benzene; and halocarbons such as dichloromethane or chloroform. Scheme 6 lb Ic It is recognized that some reagents and reaction conditions described above for preparing compounds of Formula I may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as it is depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formula I. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular sequence presented to prepare the compounds of Formula I. One skilled in the art will also recognize that compounds of Formula I and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents. Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. l H NMR spectra are reported in ppm downfield from tetramethylsilane; s is singlet, d is doublet, t is triplet, q is quartet, m is multiplet, dd is doublet of doublets, dt is doublet of triplets, br s is broad singlet. Example 1 Preparation of 2,4-Dic oro-N-[[3-chloro-5-faifluoromemylV2-pyridinyl]methyll-6-methyl- 3-pyridrnecarboxamide( Compound 8 of Index Table B): Step A: Preparation of 2.4-Dichloro-N-[[3-chloro-5- trifluoromethyl)-2- pwidmyl methyl]-6-me yl-3-pyridinecarboxamide Compound 8 was prepared by using 2-aminomethyl-3-chloro-5- trifluoromemylpyridine hydrochloride (prepared as described in WO99/42447). 2,4-dichoro- 6-methyl-3-pyridine carbonyl chloride (0.65 g) in 2 mL of methylene chloride was added to a solution of 2-arrώ omemyl-3-chloro-5- fluoromemylpyridine hydrochloride (0.79 g) and triethylamine (0.68 g) in 10 mL of methylene chloride at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was then poured on top of a one-inch silica gel plug, eluted with 30 mL of methylene chloride and the eluent was rotary evaporated to yield 0.69 g of the amide (Compound 8), a compound of the invention. i HΝMR (CDC1 3 ; 300 MHz) δ 2.57 (s,3H), 4.96 (m,2H), 7.22 (s,lH), 7.48 (bs, IH), 8.00 (s,lH), 8.71 (s,lH). Example 2 Preparation of 2^-Dic oro-N-[[3-chloro-5-rtrifluorome yl)-2-pyridrnyl]methyl]-3- pyridinecarboxamide Step A: Preparation of 2.4-dichloropyridine A solution of 6.7 g of 4-nitropyridine N-oxide in POCl was refluxed for 3 hours and then cooled to room temperature. The solvent was removed under vacuum to leave an oily residue. Saturated sodium bicarbonate solution (200 mL)was carefully added, followed by extraction with methylene chloride (2X). The methylene chloride was then removed under vacuum to provide an oil that was filtered through a plug of silica gel, eluting with 20% ethyl acetate in hexanes. Removal of the solvent xmder vacuum left 1.6 g of an oil. lH ΝMR (CDC1 3 ; 300 MHz) S 7.25(d of d,lH, J is 1.7,5.4 Hz), 7.38(d,lH, J is 1.7 Hz), 8.31(d,lH, Jis 5.4 Hz). Step B: Preparation of 2.4-dichloro-3-pyridine carboxaldehyde Under nitrogen, a solution of 1.6 g of 2,4-dichloropyridine in 5 mL dry tetrahydrofuran (THF) was added to a solution of 6 mL of hthium diisopropyl amide in 25 mL of THF at -70 °C, followed by stirring at this temperature for 3 hours. Then 1 mL of dry NN- dimethylformamide was added at -70 °C followed by stirring at this temperature for 1 hour. Then 25 mL of saturated ammonium chloride solution was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with 25 mL of water and extracted with ethyl acetate (2X). The combine organic phases were distilled under vacuum to give solids that were dissolved in 5 mL of methylene chloride and filtered through silica gel, eluting with 100% methylene chloride. Removal of the solvent under vacuum provided the title intermediate as a solid. lHΝMR (CDCl 3 ; 300 MHz) 57.41 (d,lH, J is 5.3 Hz), 8.42 (d,lH, J is 5.2 Hz), 10.5 (s,lH). Step C: Preparation of 2.4-dichloronicotinic acid A solution of 0.40 g of the aldehyde from Step B was dissolved in 6 mL of THF and then added to a solution of 0.27 g of sodium chlorite and 0.29 g of sulfamic acid in 6 mL of water. The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with 1 N sodium hydroxide (10 mL) and extracted with diethyl ether (IX). The aqueous layer was then acidified with concentrated HCl, extracted with methylene chloride (2X), and the combine methylene chloride extracts were dried over magnesium sulfate. The methylene chloride was removed under vacuum to give 0.22 g of a solid. 1HΝMR (CDC1 3 ; 300 MHz) δ 7.38(d,l H, J is 5.4 Hz), 8.40(d,lH, J is 5.5 Hz), 8.60 (bs,lH). Step D: Preparation of 2.4-Dichloro-N-rr3-chloro-5-ftrifluoromethylV2- Pyridinyl]memyl]-3-ρyridinecarboxamide A solution of 0.22 g of the acid from Step C was refluxed in thionyl chloride for 1 hour followed by removal of the solvent under vacuum to give an oil. The oil was dissolved in 1 mL of methylene chloride and added to a solution of 2-aminomethyl-3-chloro-5- trifluoromethylpyridine hydrochloride (0.25 g) and triethylamine (0.20 g) in 9 mL of methylene chloride at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was then filtered through silica gel, eluting with 100% methylene chloride. Removal of the solvent under vacuum provided the title compound as a solid, m.p. 122-124 °C. Example 3 Preparation of 2.4-DicMoro-N-[l- 3-chloro-5- trifluorome yl)-2-pyridmyl1ethyl]-3- pyridinecarboxamide Step A: Preparation of 3-Chloro-α-methyl-5-(trifluoromethylV2- pyridinemethanamine N-(diphenylmethylene)glycine ethyl ester (2.25 g) was added to a suspension of sodium hydride (0.74 g of 60% oil dispersion) in 20 mL of dry NN-dimethylformamide at room temperature, resulting in vigorous gas evolution. After stirring at room temperature for five minutes, 2 g of 2,3-dichloro-5-trifluoromethylpyridine was added, followed by stirring at room temperature for 1 hour. Then 0.80 mL of methyl iodide was added followed by stirring at room temperature overnight. The reaction mixture was poured onto ice water, extracted with diethyl ether (2X), and distilled under vacuum to remove the solvent leaving an oil. The oil was then refluxed in 6 N HCl overnight. The reaction mixture was cooled to room temperature, made basic with solid sodium carbonate and extracted with diethyl ether (2X). The combined extracts were dried over magnesium sulfate and distilled under vacuum to remove the solvent, leaving 1.5 g of an oil. !HΝMR (CDC1 3 ; 300 MHz) δ 1.4(d,3H, J is 6.6Hz), 4.6(bs,l H), 7.88(m,l H), 8.75(bs,l H). Step B: Preparation of 2.4-Dichloro-N-[l-[3-chloro-5-(trifluoromethyl -2- p yridinyl]ethyl] -3 -pyridinecarboxamide 2,4-Dichloronicotinoyl chloride (0.40 g), made as in Example 1, Step C, was added to a solution of the amine intermediate from Step A (0.66 g) and triethylamine (0.70 g) in 30 mL of methylene chloride at room temperature followed by stirring overnight. The reaction mixture was distilled under vacuum to remove the solvent, giving an oil that was filtered through silica gel using 100% methylene chloride as the eluent. The solvent was then removed under vacuum to give the title compound, a compound of the invention, as a red oil. lHΝMR (CDCl 3 ; 300 MHz) δ 1.62 (d, 3H,J is 6.7 Hz), 5.48 (m,l H), 7.35(d,l H is 5.2 Hz), 7.40(d,l H,J is 6.9), 7.99(d,l H,J is 1.8 Hz), 8.34(d,l H,J is 5.2), 8.70(s,l H). Example 4 Preparation of (+V2.4-Dichloro-N-[ 1 -[3-chloro-5-rtrifluoromethylV2-pyridinyl]ethyll-3- pyridinecarboxamide Step A: Resolution of 3-Chloro-α-methyl-5-(trifluoromethylV2- pyridinemethanamine: (-)-Menthyl chloroformate (0.92 g) was added to a solution of the alpha-methyl amine from Example 3, Step A (l g) and triethylamine (1.2 mL) in 25 mL of THF at room temperature followed by stirring at room temperature for 30 minutes. The solvent was then removed under vacuum to give an oil comprising two menthylcarbamate diastereomers that were separated via column chromatography (5% diethyl ether in hexanes as eluent) to give 0.20 g of the more polar diastereomer as an oil. This oil was then refluxed in 5 mL of trifluoroacetic acid for 4 hours to cleave the menthylcarbamate. The reaction mixture was allowed to cool to room temperature and diluted with water (30 mL), made basic with solid sodium carbonate and extracted with methylene chloride. The organic layer was dried over magnesium sulfate and distilled under vacuum to give 60 mg of the enantiomerically- enriched amine intermediate as an oil. 1H ΝMR (CDC1 3 ; 300 MHz) δ 1.41(d,3 H, J is 6.7 Hz), 1.9(bs,2 H), 4.60(m,lH), 7.88(m,lH), 8.74(s,l H). Step B: Preparation of <;+V2.4-Dichloro-N-ri-ι r 3-chloro-5-(trifluoromethylV2- pyridinyl]ethyl]-3-pyridinecarboxamide: 2,4-Dichloronicotinoyl chloride (0.56 g), made as in Example 1, Step C was added to a solution of the enantiomerically-enriched amine from Step A (60 mg) and triethylamine (54 mg) in 10 mL of methylene chloride at room temperature followed by stirring overnight. The reaction mixture was then filtered through silica gel using 100% methylene chloride as the eluent. The solvent was removed under vacuum to give the title compound, a compound of the invention, as a solid, m.p. 110-111 °C. Polarimetric measurements of a solution of approximately 2 mg of the title compound in 1 mL of CDC1 3 rotates plane polarized light in the (+) or dextro direction. The enantiomer of Example 4, (-)-2,4-Dichloro-N-[-l-[3-chloro-5-(trifluoromethyl)-2- pyridmyl]etliyl]-3-pyridinecarboxamide, was prepared in analogoous fashion using 3-chloro- -memyl-5-(1rifluoromethyl)-2-pyrid^emethanamine that has been emiched in the opposite enantiomer from that obtained in Example 4, Step A. Example 5 Preparation of N-[l-r5-bromo-3-chloro-2-pyridiny ethyl1-2.4-dichloro-3- pyridinecarboxamide Step A: Preparation of 5-bromo-3-chloro-2f lH)-pyridone A solution of 6.2g of potassium chlorate in 100 mL of water was added to a solution of 25g of 5-bromo-2-pyridone in 100 mL concentrated HCl pre-heated to 50 °C to 60 °C to form a thick precipitate that was stirred for 5 min. Then, 60 mL of water was added to facilitate stirring and the mixture was stirred at room temperature overnight. The reaction mixture was filtered, triturated with water (2X), and the precipitate suction-dried to yield 17.7 g of the desired intermediate as a solid. NMR (CDC1 3 , 300MHz): δ 7.53 (d, IH, J is 2.6Hz), 7.75 (d, IH, J is 2.5 Hz) Step B: Preparation of 5-bromo-2.3-dichloropyridine The product of Step A (17.7g) and 10 g of PC1 5 were combined into 100 mL POCl 3 , and the mixture was refluxed for 4 hours with scrubbing. The reaction mixture was concentrated under reduced pressure to remove most of the POCl 3 , carefully poured into warm water, cooled to room temperature and then extracted with methylene chloride (2X). The combined extracts were dried over magnesium sulfate and concentrated to give an oil which was subjected to column chromatography (8:2/hexanes:EtOAc) to give 4.2g of the desired intermediate as an oil. NMR (CDC1 3 ; 300MHz): δ 7.94(d, IH, J is 2.2 Hz), 8.37(d, IH, J is 2.3 Hz). Step C: Preparation of 5-Bromo-3-chloro-α-methyl-2-pyridinemethanamine hydrochloride Under nitrogen, 4.1 g of the title compound from Step B was added to a suspension of sodium hydride (60% oil suspension) in 30 mL of dry NN-dimethylformamide, cooled to 0 C. Ν-(Diphenylmethylene)glycine ethyl ester (4.6 g) was added in portions with no exotherm, and the mixture was stirred at room temperature for 3 hours. Then, 3.4 mL of methyl iodide was added at < 30 °C and the reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with water and extracted with diethyl ether (2X). The combined extracts were washed with saturated brine (IX) and reduced in vacuo to an oil that was then refluxed in 50 mL of 12N HCl for 4 hours. The reaction mixture was reduced in vacuo to an oil, cooled, and slurried with diethyl ether overnight. The ether was then decanted off and the residue was dried in a vacuum oven to give 1.3 g of the desired intermediate as a solid. NMR(CDC1 3 ; 300MHz): 1.40 and 1.46(2 doublets, 3H, J is 7.0 Hz), 4.7 (m, IH), 8.48(d, IH, J is 1.8), 8.6(bs, 3H), 8.79(d, IH, J is 1.9 Hz). Step D: Preparation of N-[l-(5-bromo-3-chloro-2-pyridinyl ethyll-2.4-dichloro-3- pyridinecarboxamide The product of Step C (0.80 g), 1.21 mL of triethyl amine and 0.62g of 2,4-dichloronicotinoyl chloride were combined in that order at < 20 °C in 25 mL of methylene chloride, and the mixture was stirred at room temperature overnight. The reaction mixture was reduced in vacuo to produce the title compound, a compound of the invention, as a solid. MR (CDC1 3 ; 300MHz): δ 1.59(d, 3H, J is 6.6 Hz), 5.75(m, IH), 7.3(bs, IH), 7.34(d, IH, Jis 5.2 Hz), 7.91(d, IH, J is 1.9 Hz), 8.33(d, IH, J is 5.4 Hz), 8.49(d, IH, J is 1.9 Hz). Example 6 Preparation of 2.4-Dic oro-N-[l-β.5-dicMoro-2-pyridmyl ethyl]-3-pyridinecarboxamide Example 6 was prepared in analogous fashion to Example 5 using 2-bromo-3,5- dichloropyridine as the starting material and subjecting this material to conditions analogous to those described in Steps C (to prepare 3,5-chcMoro-α-memyl-2-pyrio^ememanamine) and D of Example 5 to give the title compound, a compound of the invention, as a solid. ΝMR (CDC1 3 ; 300MHz): δ 1.58(d, 3H, is 6.6Hz), 5.7-5.8(m, IH), 7.4(m, 2H), 7.77(m, IH), 8.35(m, IH), 8.40(m, IH). By the procedures described herein together with methods known in the art, the following compounds of Tables 1-9 can be prepared. The following abbreviations are used in the Tables which follow: t is tertiary, s is secondary, n is normal, i is iso, c is cyclo, Me is methyl, Et is ethyl, Pr is propyl, i-Pr is isopropyl, Bu is butyl, Phis phenyl, OMe is methoxy, OEt is ethoxy, SMe is methylthio, SEt is ethylthio, CΝ is cyano, ΝO 2 is nitro, TMS is trimethylsilyl, S(O)Me is methylsulfinyl, and S(O) 2 Me is methylsulfonyl. The substituents M, Q and R are equivalent to independent R 5 substituents that have been located in the positions indicated. The substituents T, U and V are equivalent to independent R 6 substituents that have been located in the positions indicated. Table 1 T u V T u V Me Me Me Br Me Me Me Me F Br Me F Me Me CI Br Me CI Me Me Br Br Me Br Me Me CF Br Me CF 3 Me Me N0 2 Br Me N0 2 Me Me OMe Br Me OMe F Me Me CF 3 Me Me F Me F CF 3 Me F F Me CI CF 3 Me CI F Me Br CF 3 Me Br F Me CF 3 CF 3 Me CF 3 F Me N0 2 CF 3 Me N0 2 F Me OMe CF 3 Me OMe CI Me Me N0 2 Me Me CI Me F N0 2 Me F CI Me CI N0 2 Me CI CI Me Br N0 2 Me Br CI Me CF N0 2 Me CF 3 CI Me N0 2 N0 2 Me N0 2 CI Me OMe N0 2 Me OMe T u V T U V Me F Me Br F Me Me F F Br F F Me F CI Br F CI Me F Br Br F Br Me F CF 3 Br F CF Me F N0 2 Br F N0 2 Me F OMe Br F OMe F F Me CF 3 F Me F F F CF 3 F F F F CI CF 3 F CI F F Br CF 3 F Br F F CF 3 CF 3 F CF 3 F F N0 2 CF 3 F N0 2 F F OMe CF 3 F OMe CI F Me N0 2 F Me CI F F N0 2 F F CI F CI N0 2 F CI CI F Br N0 2 F Br CI F CF 3 N0 2 F CF 3 CI F N0 2 N0 2 F N0 2 CI F OMe N0 2 F OMe T U V T U V Me CI Me Br CI Me Me CI F Br CI F Me CI CI Br CI CI Me CI Br Br CI Br Me CI CF Br CI CF 3 Me CI N0 2 Br CI N0 2 Me CI OMe Br CI OMe F CI Me CF 3 CI Me F CI F CF 3 CI F F CI CI CF 3 CI CI F CI Br CF 3 CI Br F CI CF 3 CF 3 CI CF 3 F CI N0 2 CF 3 CI N0 2 F CI OMe CF CI OMe CI CI Me N0 2 CI Me CI CI F N0 2 CI F CI CI CI N0 2 CI CI CI CI Br N0 2 CI Br CI CI CF 3 N0 2 CI CF 3 CI CI N0 2 N0 2 CI N0 2 CI CI OMe N0 2 CI OMe T u V T U V Me Br Me Br Br Me Me Br F Br Br F Me Br CI Br Br CI Me Br Br Br Br Br Me Br CF 3 Br Br CF 3 Me Br N0 2 Br Br N0 2 Me Br OMe Br Br OMe F Br Me CF 3 Br Me F Br F CF 3 Br F F Br CI CF 3 Br CI F Br Br CF 3 Br Br F Br CF 3 CF 3 Br CF 3 F Br N0 2 CF 3 Br N0 2 F Br OMe CF 3 Br OMe CI Br Me N0 2 Br Me CI Br F N0 2 Br F CI Br CI N0 2 Br CI CI Br Br N0 2 Br Br CI Br CF 3 N0 2 Br CF 3 toO toP toP toP toP toP Me H Br Br H Br Me H CF 3 Br H CF 3 Me H N0 2 Br H N0 2 Me H OMe Br H OMe F H Me CF 3 H Me F H F CF 3 H F F H CI CF H CI F H Br CF 3 H Br F H CF 3 CF 3 H CF 3 F H N0 2 CF H N0 2 F H OMe CF 3 H OMe CI H Me N0 2 H Me CI H F N0 2 H F CI H CI N0 2 H CI CI H Br N0 2 H Br CI H CF 3 N0 2 H CF 3 CI H N0 2 N0 2 H N0 2 CI H OMe N0 2 H OMe T U V T U V OMe Me Me OMe Br Me OMe Me F OMe Br F OMe Me CI OMe Br CI OMe Me Br OMe Br Br OMe Me CF 3 OMe Br CF OMe Me N0 2 OMe Br N0 2 OMe Me OMe OMe Br OMe OMe F Me OMe CF 3 Me OMe F F OMe CF F OMe F CI OMe CF 3 CI OMe F Br OMe CF 3 Br OMe F CF 3 OMe CF 3 CF 3 OMe F N0 2 OMe CF 3 N0 2 OMe F OMe OMe CF 3 OMe OMe CI Me OMe N0 2 Me OMe CI F OMe N0 2 F OMe CI CI OMe N0 2 CI OMe CI Br OMe N0 2 Br CD >ιj O hrj O hrj O hrj hrj hrj hrj hrj hrj i- F H CI CF H CI F H Br CF 3 H Br F H CF 3 CF 3 H CF 3 F H N0 2 CF 3 H N0 2 F H OMe CF 3 H OMe CI H Me N0 2 H Me CI H F N0 2 H F CI H CI N0 2 H CI CI H Br N0 2 H Br CI H CF 3 N0 2 H CF 3 CI H N0 2 N0 2 H N0 2 CI H OMe N0 2 H OMe T U V T U V OMe Me Me OMe Br Me OMe Me F OMe Br F OMe Me CI OMe Br CI OMe Me Br OMe Br Br OMe Me CF 3 OMe Br CF 3 OMe Me N0 2 OMe Br N0 2 OMe Me OMe OMe Br OMe OMe F Me OMe CF 3 Me OMe F F OMe CF 3 F OMe F CI OMe CF 3 CI OMe F Br OMe CF 3 Br OMe F CF 3 OMe CF 3 CF 3 OMe F N0 2 OMe CF 3 N0 2 OMe F OMe OMe CF 3 OMe OMe CI Me OMe N0 2 Me OMe CI F OMe N0 2 F OMe CI CI OMe N0 2 CI OMe CI Br OMe N0 2 Br OMe CI CF 3 OMe N0 2 CF 3 OMe CI N0 2 OMe N0 2 N0 2 OMe CI OMe OMe N0 2 OMe OMe H Me OMe H Br OMe H F OMe H CF 3 OMe H CI OMe H N0 2 OMe H OMe OMe OMe Me OMe OMe CF 3 OMe OMe F OMe OMe N0 2 OMe OMe CI OMe OMe OMe OMe OMe Br Table 3 T u V T U V Me Me Me Br Me Me Me Me F Br Me F Me Me CI Br Me CI Me Me Br Br Me Br Me Me CF 3 Br Me CF 3 Me Me N0 2 Br Me N0 2 Me Me OMe Br Me OMe F Me Me CF 3 Me Me F Me F CF 3 Me F F Me CI CF 3 Me CI F Me Br CF 3 Me Br F Me CF CF 3 Me CF 3 F Me N0 2 CF 3 Me N0 2 F Me OMe CF 3 Me OMe CI Me Me N0 2 Me Me CI Me F N0 2 Me F CI Me CI N0 2 Me CI CI Me Br N0 2 Me Br CI Me CF N0 2 Me CF 3 CI Me N0 2 N0 2 Me N0 2 CI Me OMe N0 2 Me OMe T U V T U V Me F Me Br F Me Me F F Br F F Me F CI Br F CI to to to t o o o o n o o o o o o Cd td td td Cd Cd td Cd td Cd Cd td td td td td Cd Cd Cd td td O o Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω G a ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi Cd Cd Cd d Cd Cd Cd Cd td Cd td Cd Cd Cd Cd td td Cd Cd II II I II 1 11 11 I 11 1 II Cd Cd O Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω I I I I I I I I I I I g S S S S ^ 2 ^ 2 td td td td td td fcd Cd Cd td td td td td Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi Cd Cd Cd Cd Cd td Cd td td Cd Cd Cd Cd Cd Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω -J I I I I I I I I I I I I Ω Ω Ω Ω Ω 9 Cd Cd Cd Cd Cd Cd Cd Cd Cd Cd Cd Cd 1 11 I 11 I I 11 11 Cd II I I II td O O O O O O O O Q O Q O O O O O O O O O O O O O Cd Cd Cd td td Cd Cd Cd Cd td Cd Cd Cd II II E? Ω Ω O O Q O O O O O O O O O O O O O O O O O O O o l £ δ £ s £ £ £ m £ £ s c £ £ £ II cT £ £ c £t> Cd Cd Cd Cd £F δ cT δ I-- ON <X> S ffi ST> © & & CS t ft s ^ s Ά f S s ω s> s < s ω s> s <o Mi s> s 0) s ω __ ^ fe O O O o O O O C o O O O O CO- 0 a CO O - 1 1 3 a. I CS o o o υ o o o o o o υ o o o o o o o o o o o m PQ pq PQ q m m m m 05 ffl PQ m a ffi cs O o ft & f ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi O cQ δ o o o a o ε o δ ffi fi O O O O co co ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi co co ca c co c c co co co o co O ffi ffi ffi ffi ffi ffi ffi ffi 8 CS o o o o o O o O o o o o o o o o o o O D o o o m m m m m m m m m Br SOCHF 2 H Br SOCHF 2 Me Br SOCH 2 CF 3 H Br SOCH 2 CF 3 Me Br SOCF 2 CF 3 H Br SOCF 2 CF 3 Me Br SOCF 2 CF 2 H H Br SOCF 2 CF 2 H Me Br SOCHFCF3 H Br SOCHFCF 3 Me Br S0 2 CF 3 H Br S0 2 CF 3 Me Br S0 2 CHF 2 H Br S0 2 CHF 2 Me Br S0 2 CH 2 CF 3 H Br S0 2 CH 2 CF 3 Me Br S0 2 CF 2 CF 3 H Br S0 2 CF 2 CF 3 Me Br S0 2 CF 2 CF 2 H H Br S0 2 CF 2 CF 2 H Me Br S0 CHFCF 3 H Br S0 2 CHFCF 3 Me Br CN H Br CN Me H CI CI Me CI CI H Br CI Me Br CI H CF CI Me CF 3 CI H OCF 3 CI Me OCF 3 CI H OCHF 2 CI Me OCHF 2 CI H OCH 2 CF 3 CI Me OCH 2 CF 3 CI H OCF 2 CF 3 CI Me OCF 2 CF 3 CI H OCF 2 CF 2 H CI Me OCF 2 CF 2 H CI H OCHFCF 3 CI Me OCHFCF3 CI H SCF 3 CI Me SCF 3 CI H SCHF 2 CI Me SCHF 2 CI H SCH 2 CF 3 CI Me SCH 2 CF 3 CI H SCF 2 CF 3 CI Me SCF 2 CF 3 CI H SCF 2 CF 2 H CI Me SCF 2 CF 2 H CI H SCHFCF3 CI Me SCHFCF3 CI H SOCF CI Me SOCF3 CI H SOCHF 2 CI Me SOCHF 2 CI H SOCH 2 CF 3 CI Me SOCH 2 CF CI H SOCF 2 CF 3 CI Me SOCF 2 CF CI H SOCF 2 CF 2 H CI Me SOCF 2 CF 2 H CI H SOCHFCF3 CI Me SOCHFCF3 CI H S0 2 CF 3 CI Me S0 2 CF 3 CI H S0 2 CF£F 2 CI Me S0 2 CHF 2 CI H S0 2 CH 2 CF 3 CI Me S0 2 CH 2 CF 3 CI H S0 2 CF 2 CF 3 CI Me S0 2 CF 2 CF 3 CI H S0 2 CF 2 CF 2 H CI Me S0 2 CF 2 CF 2 H CI 90 S H O α. i rl- ft o CI H OCH2CF3 CI Me OCH2CF3 CI H OCF2CF2H CI Me OCF2CF2H CI H SCF3 CI Me SCF3 CI H SCHF2 CI Me SCHF2 Br SCF 3 H Br SCF3 Me Br SCHF 2 H Br SCHF 2 Me Br SCH 2 CF 3 H Br SCH 2 CF 3 Me Br SCF 2 CF 3 H Br SCF 2 CF 3 Me Br SCF 2 CF 2 H H Br SCF 2 CF 2 H Me Br SCHFCF3 H Br SCHFCF3 Me Br SOCF3 H Br SOCF3 Me Br SOCHF 2 H Br SOCHF 2 Me Br SOCH 2 CF 3 H Br SOCH 2 CF 3 Me Br SOCF 2 CF 3 H Br SOCF 2 CF 3 Me Br SOCF 2 CF 2 H H Br SOCF 2 CF 2 H Me Br SOCHFCF3 H Br SOCHFCF3 Me Br S0 2 CF H Br S0 2 CF 3 Me Br S0 2 CHF 2 H Br S0 2 CHF 2 Me Br S0 2 CH 2 CF 3 H Br S0 2 CH 2 CF 3 Me Br S0 2 CF 2 CF 3 H Br SO2CF2CF3 Me Br S0 2 CF 2 CF 2 H H Br S0 2 CF 2 CF 2 H Me Br S0 2 CHFCF 3 H Br S0 2 CHFCF 3 Me Br CN H Br CN Me H CI CI Me CI CI H Br CI Me Br CI H CF 3 CI Me CF3 CI H OCF3 CI Me OCF3 CI H OCHF 2 CI Me OCHF 2 CI H OCH 2 CF 3 CI Me OCH 2 CF 3 CI H OCF 2 CF 3 CI Me OCF 2 CF 3 CI H OCF 2 CF 2 H CI Me OCF 2 CF 2 H CI H OCHFCF 3 CI Me OCHFCF3 CI H SCF 3 CI Me SCF 3 CI H SCHF 2 CI Me SCHF 2 CI H SCH 2 CF 3 CI Me SCH 2 CF 3 CI H SCF 2 CF 3 CI Me SCF 2 CF 3 CI H SCF 2 CF 2 H CI Me SCF 2 CF 2 H CI H SCHFCF CI Me SCHFCF 3 CI P j l l 1>1 ON O O O O O O O O O O O O O O O PQ PQ PQ PQ pq pq pq pq ffl ffl n a n pq ffl ffl PQ (S3 m S S S ffi cs O ft a ft cs _ | H ft O O a s O ft O ■ co ft ffi ffi ffi ffi ffi ffi o m δ o p p P co aco ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi O O o o o o o o o o o o o o o o o o m m m m m pQ m m pQ pQ pQ m pQ PQ m rø p-i p-i PQ ffi ffi ffi td Cd td td Cd O O O O O O O O Ω Ω <^ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 O P Oy ^ O^ ffift ffift ffift ffift ffift ffift ffift ffift ffi ^ ^O o o o o o o o o o o o o o n o O o o P P ffi ffi ffi ffi ffi co o Q O O O Ω hrj p ιι d Ω ■ ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi Ω Ω Tj Ωj Ω Ω Ω OJ n t Q o S B to 3 7] Cd Cd Cd Cd Cd H I 1 I 11 O O O O O O O O O Ω Ω O O O O O O O O O O O O O O O O O O O O O O cf c Ωo o Ωo o o O o O Q o O _ --J Cd o £ £ δ £ £ s s £ £ £ £ £ £ £ g g £ £ Tj ? ? £ £ £ s OJ to O O to Tj hrj to OJ ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi Cd Cd Cd Cd Cd d te Cd Cd d Cd Cd Cd Cd Cd Cd Cd td td td Cd Cd Cd Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi Os z z % % z z % % % z % % % * w w w * * w * w w Cd Cd Cd Cd ϋd td Cd Cd Cd Cd Cd Cd 1 td o Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω | | | | | | | | | | | | | | | | | | | | | | | <u ω ω cs θ O θ 8 θ O O θ 8 θ O O θ m m PQ PQ O θ 8 m m m m m m m m m m m m m m m s s s e ffi R g ft ° δ ft CS ft ffi ffi ft ft ffi ffi ffi ffi ffi ffi o m δ o p p p co a ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi o υ o ffi ft cs ft ft ft •5, ft cs O 0 U ft ffi cs CS ft rs (.) CS cs 1 t cs O f ft CS δ 0 δ cS δ 0 a a ft t CS ft f O 0 0 cS ft 8 CS δ cs ft 0 O a CS CS 0 a CS ffi a ) CS 8 CS rs rs t ff^ ft ft 0 CS u 0 f cs rs δ CS δ r CS O P O O 0 0 0 a 0 δ 0 2 CO CO CO CO B 0 s P δ 0 δ P P P P P P n CS CO δ ffi ffi ffi ffi ffi ffi ffi ffl ffi CO o a i CO υ OO CO CO CO CO CO CO O υO co CO CO CO O O O O m O ft 0 0 0 0 0 0 0 0 0 0 0 0 0 0 o m m m m m m m m m m m m PQ m m PQ Q PQ rø ffi ffi ffi υ Cl SCH 2 CF 3 H Cl SCH 2 CF 3 Me CI SCF 2 CF 3 H Cl SCF 2 CF 3 Me Cl SCF 2 CF 2 H H Cl SCF 2 CF 2 H Me Cl SCHFCF 3 H Cl SCHFCF 3 Me Cl SOCF 3 H Cl SOCF 3 Me Cl SOCHF 2 H Cl SOCHF 2 Me Cl SOCH 2 CF 3 H Cl SOCH 2 CF Me Cl SOCF 2 CF 3 H Cl SOCF 2 CF 3 Me Cl SOCF 2 CF 2 H H Cl SOCF 2 CF 2 H Me Cl SOCHFCF3 H Cl SOCHFCF3 Me Cl S0 2 CF 3 H Cl S0 2 CF 3 Me Cl S0 2 CHF 2 H Cl S0 2 CHF 2 Me Cl S0 2 CH 2 CF 3 H Cl S0 2 CH 2 CF 3 Me Cl S0 2 CF 2 CF3 H Cl S0 2 CF 2 CF 3 Me Cl S0 2 CF 2 CF 2 H H Cl S0 2 CF 2 CF 2 H Me Cl S0 2 CHFCF 3 H Cl S0 2 CHFCF 3 Me Cl CN H Cl CN Me Cl H Cl Cl Me Cl Cl H Br Cl Me Br Cl H CF3 Cl Me CF3 Cl H 0CF3 Cl Me OCF3 Cl H 0CHF2 Cl Me OCHF2 Cl H OCH2CF3 Cl Me OCH2CF3 Cl H OCF2CF2H Cl Me OCF2CF2H Cl H SCF3 Cl Me SCF3 Cl H SCHF2 Cl Me SCHF2 Br SCF 3 H Br SCF 3 Me Br SCHF 2 H Br SCHF 2 Me Br SCH 2 CF 3 H Br SCH 2 CF 3 Me Br SCF 2 CF 3 H Br SCF 2 CF Me Br SCF 2 CF 2 H H Br SCF 2 CF 2 H Me Br SCHFCF3 H Br SCHFCF 3 Me Br SOCF3 H Br SOCF3 Me Br SOCHF 2 H Br SOCHF 2 Me Br SOCH 2 CF 3 H Br SOCH 2 CF 3 Me Br SOCF 2 CF H Br SOCF 2 CF 3 Me Br SOCF 2 CF 2 H H Br SOCF 2 CF 2 H Me Br SOCHFCF3 H Br SOCHFCF 3 Me ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω 9 O O O Q o Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω 8 o o 8 o o 8 8 8 m m m m m rø m m m m m m m m m m m m m m m m m m m m m m ffi ft CS, cs O o ft ft ffi ffi ft ft ft 8 rø O O O O o o P P P P co co ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi O PQ ft 0 0 rto ort ro or rto mJ5 mJs m l s m , i m , m , - | m , - | m , -ι m'-ι m'-ι m'-ι miH miH miH miH O miH miH miH miH m m m m m m m m m O O O O O O O O O O O O O O O O O O O O O O O O O O O O O PQ PQ m m m PQ PQ m ffi CS. es O ft O ft £ cs ft ft _ iπ ft O O O O iff ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi o m o o o o o co & ffi ffi ffi ffi ffi ffi ffi ffi Br SOCF 2 CF 3 H Br SOCF 2 CF 3 Me Br SOCF 2 CF 2 H H Br SOCF 2 CF 2 H Me Br SOCHFCF3 H Br SOCHFCF3 Me Br S0 2 CF 3 H Br S0 2 CF 3 Me Br S0 2 CHF 2 H Br S0 2 CHF 2 Me Br S0 2 CH 2 CF 3 H Br S0 2 CH 2 CF Me Br S0 2 CF 2 CF H Br S0 2 CF 2 CF 3 Me Br S0 2 CF 2 CF 2 H H Br S0 2 CF 2 CF 2 H Me Br S0 2 CHFCF 3 H Br S0 2 CHFCF 3 Me Br CN H Br CN Me H Cl Cl Me Cl Cl H Br Cl Me Br Cl H CF 3 Cl Me CF 3 Cl H OCF 3 Cl Me OCF3 Cl H OCHF 2 Cl Me OCHF 2 Cl H OCH 2 CF 3 Cl Me OCH 2 CF 3 Cl H OCF 2 CF 3 Cl Me OCF 2 CF 3 Cl H OCF 2 CF 2 H Cl Me OCF 2 CF 2 H Cl H OCHFCF3 Cl Me OCUFCF3 Cl H SCF3 Cl Me SCF 3 Cl H SCHF 2 Cl Me SCHF 2 Cl H SCH 2 CF 3 Cl Me SCH 2 CF 3 Cl H SCF 2 CF 3 Cl Me SCF 2 CF 3 Cl H SCF 2 CF 2 H Cl Me SCF 2 CF 2 H Cl H SCHFCF3 CI Me SCHFCF 3 Cl H SOCF3 Cl Me SOCF3 Cl H SOCHF 2 Cl Me SOCHF 2 Cl H SOCH 2 CF 3 Cl Me SOCH 2 CF 3 Cl H SOCF 2 CF 3 Cl Me SOCF 2 CF 3 Cl H SOCF 2 CF 2 H Cl Me SOCF 2 CF 2 H Cl H SOCHFCF3 Cl Me SOCHFCF 3 Cl H S0 2 CF 3 Cl Me S0 2 CF 3 Cl H S0 2 CHF 2 Cl Me S0 2 CHF 2 Cl H S0 2 CH 2 CF 3 Cl Me S0 2 CH 2 CF 3 Cl H S0 2 CF 2 CF 3 Cl Me S0 2 CF 2 CF 3 Cl H S0 2 CF 2 CF 2 H Cl Me S0 2 CF 2 CF 2 H Cl H S0 2 CHFCF 3 Cl Me SO2CHFCF3 Cl H CN Cl Me CN Cl TisClandVandU are both Me fi!§ -H Ho rt υ rt Ho Ho -oH Ho Ho Ho -o, H Ho -, -α Ho ffi ft cs rπ cs O δ δ t ft O en cs δ δ cs ft f a ft O ft t o « o" o f ft o ft a ffi" ft ft δ f y o o o o O O υ PQ Ot O P P o o co co co cs o o PQ m Js a Ja Ja '- ι *-ι ! -ι '-ι q m PQ PQ pq pq PQ PQ PQ m m m PQ m PQ to (S s 3 ^ s s s s s s ^ s ^ ^ s CS en ft ft ffi c oo oo ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi O O O O O O O O O O O O O O O O ffi o r orϊ mJs m's mi! m ! s mJa m ! s m'- | m*-< m , - ι m>-< m'-ι mi-ι m*-ι mΗ miH miH miH miH Cl SOCHF 2 H Cl SOCHF 2 Me Cl SOCH 2 CF 3 H Cl SOCH 2 CF 3 Me Cl SOCF 2 CF 3 H Cl SOCF 2 CF 3 Me Cl SOCF 2 CF 2 H H Cl SOCF 2 CF 2 H Me Cl SOCHFCF3 H Cl SOCHFCF3 Me Cl S0 2 CF 3 H Cl S0 2 CF 3 Me Cl S0 2 CHF 2 H Cl S0 2 CHF 2 Me Cl S0 2 CH 2 CF 3 H Cl S0 2 CH 2 CF 3 Me Cl S0 2 CF 2 CF 3 H Cl S0 2 CF 2 CF 3 Me Cl S0 2 CF 2 CF 2 H H Cl S0 2 CF 2 CF 2 H Me Cl S0 2 CHFCF 3 H Cl S0 2 CHFCF 3 Me Cl CN H Cl CN Me Cl H Cl CI Me Cl Cl H Br Cl Me Br Cl H CF3 Cl Me CF3 Cl H 0CF3 Cl Me 0CF3 Cl H 0CHF2 Cl Me 0CHF2 Cl H OCH2CF3 Cl Me OCH2CF3 Cl H OCF2CF2H Cl Me OCF2CF2H Cl H SCF3 CI Me SCF3 Cl H SCHF2 Cl Me SCHF2 Br Cl H Br Cl Me Br Br H Br Br Me Br CF 3 H Br CF 3 Me Br OCF3 H Br OCF 3 Me Br OCHF 2 H Br OCHF 2 Me Br OCH 2 CF 3 H Br OCH 2 CF 3 Me Br OCF 2 CF 3 H Br OCF 2 CF 3 Me Br OCF 2 CF 2 H H Br OCF 2 CF 2 H Me Br OCHFCF 3 H Br OCHFCF 3 Me Br SCF 3 H Br SCF 3 Me Br SCF£F 2 H Br SCHF 2 Me Br SCH 2 CF 3 H Br SCH 2 CF 3 Me Br SCF 2 CF 3 H Br SCF 2 CF 3 Me Br SCF 2 CF 2 H H Br SCF 2 CF 2 H Me Br SCFIFCF 3 H Br SCHFCF3 Me Br SOCF3 H Br SOCF 3 Me Br SOCHF 2 H Br SOCHF 2 Me Br SOCH 2 CF 3 H Br SOCH 2 CF 3 Me Br SOCF 2 CF 3 H Br SOCF 2 CF 3 Me Br SOCF 2 CF 2 H H Br SOCF 2 CF 2 H Me Br SOCHFCF 3 H Br SOCHFCF3 Me Br S0 2 CF 3 H Br S0 2 CF 3 Me Br S0 2 CHF 2 H Br S0 2 CHF 2 Me Br S0 2 CH 2 CF 3 H Br S0 2 CH 2 CF 3 Me Br S0 2 CF 2 CF 3 H Br S0 2 CF 2 CF3 Me Br S0 2 CF 2 CF 2 H H Br S0 2 CF 2 CF 2 H Me Br S0 2 CHFCF 3 H Br S0 2 CHFCF 3 Me Br CN H Br CN Me H Cl Cl Me Cl Cl H Br Cl Me Br Cl H CF 3 Cl Me CF 3 Cl H OCF Cl Me OCF 3 Cl H OCHF 2 Cl Me OCHF 2 Cl H OCH 2 CF 3 Cl Me OCH 2 CF 3 Cl H OCF 2 CF 3 Cl Me OCF 2 CF 3 Cl H OCF 2 CF 2 H Cl Me OCF 2 CF 2 H Cl H OCHFCF 3 Cl Me OCHFCF 3 Cl H SCF3 Cl Me SCF 3 Cl H SCHF 2 Cl Me SCHF 2 Cl H SCH 2 CF 3 Cl Me SCH 2 CF 3 Cl H SCF 2 CF 3 Cl Me SCF 2 CF 3 Cl H SCF 2 CF 2 H Cl Me SCF 2 CF 2 H Cl H SCHFCF3 Cl Me SCHFCF3 Cl H SOCF3 Cl Me SOCF3 Cl H SOCHF 2 Cl Me SOCHF 2 Cl H SOCH 2 CF 3 Cl Me SOCH 2 CF 3 Cl H SOCF 2 CF 3 Cl Me SOCF 2 CF 3 Cl H SOCF 2 CF 2 H Cl Me SOCF 2 CF 2 H Cl H SOCHFCF 3 Cl Me SOCHFCF3 Cl H S0 2 CF 3 Cl Me S0 2 CF 3 Cl H S0 2 CHF 2 Cl Me S0 2 CHF 2 Cl H S0 2 CH 2 CF 3 Cl Me S0 2 CH 2 CF 3 Cl H S0 2 CF 2 CF 3 Cl Me S0 2 CF 2 CF 3 Cl H S0 2 CF 2 CF 2 H Cl Me S0 2 CF 2 CF 2 H Cl H S0 2 CHFCF 3 Cl Me S0 2 CHFCF 3 Cl S S o 8 8 0 8 o 0 o D o o o o δ fif cs fi f ft o f CS a CS ft ft t C ) C ) δ cs υ ft ft U O ft o rs rs cs co ft ff ft ft ff ffi ft ft o a s i o o o O i O o a CO δ m δ P P P P P P δo oo oo O CO CO ω ω ω ω ω ω ω ω αj ω ω ω αj j ju r-- O 8 m m Q m PQ rø PQ m m m PQ m m m m m m m PQ C ffiS, ffi ffi ffi ffi ffi ffi ffi ffi ffi ffl ffi ffi ffi ffi ffi ffi ffi ffi ffi υ o o o υ o o υ o o o o o o o ffi ffi co fi cS fi f ft O f tf δ ot O δ t ro f cs f t ft c δ t o cs cs f ro s O ft cs cS δ CS δ δ δ ft ffi ft tf cs O f o o cs f ft ffi ft ffi _£>• CS CS ft ft a f ot a O ffi O ft ft O O a δ t ft O O o o O a O 3 ffi cs cs δ CS cs CS cs cs CS n ft s δ t ft ft O P P P P P P 2 __, ft p f 8 8 ft o u ft o a ffi C) o a O ffi ffi ffi O o 8 O O o P O o o O P O CO CO O CO CO O O CO CO CO O CO O O O o m o o p p P P o CO O CO O CO CO o o o to to to PQ m m m m m PQ pq m m m pQ m m m m ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi o 8 8 8 0 o 8 8 8 8 m m m m m m m m m m m p m m m q m ^ ^ ^ ^ ffi ft ft r U 8 c E s £ ffi ffi ffi fi i o m o 0 0 a a f ff 0 0 8 a8 P O P P co co ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi ffi o υ o o o o o o o o o o o o o o o o m m m m m S m m m m m m © Ω Ω Ω Ω Ω O Ω Ω O O Ω O O O O O O O O O O O O t~- H O Q- cό O NH 2 H H NH 2 H Me NHCOMe H H NHCOMe H Me NHCOCF3 H H NHCOCF3 H Me SCF 3 H H SCF3 H Me SCHF 2 H H SCHF 2 H Me SCH 2 F H H SCH 2 F H Me Ph H H Ph H Me Me 3 Si H H Me 3 Si H Me I Me H I Me Me OCHF 2 Me H OCHF 2 Me Me OCH 2 F Me H OCH 2 F Me Me OCF 2 Cl Me H OCF 2 Cl Me Me OCH 2 CF 3 Me H OCH 2 CF Me Me Et Me H Et Me Me CN Me H CN Me Me NH 2 Me H NH 2 Me Me NHCOMe Me H NHCOMe Me Me NHCOCF3 Me H NHCOCF3 Me Me SCF 3 Me H SCF 3 Me Me SCHF 2 Me H SCHF 2 Me Me SCH 2 F Me H SCH 2 F Me Me Ph Me H Ph Me Me Me 3 Si Me H Me 3 Si Me Me Table 12 Q R2 U Q R2 U I H H I H Me OCHF 2 H H OCHF 2 H Me OCH 2 F H H OCH 2 F H Me OCF 2 Cl H H OCF 2 Cl H Me OCH 2 CF 3 H H OCH 2 CF 3 H Me Et H H Et H Me CN H H CN H Me NH 2 H H NH 2 H Me NHCOMe H H NHCOMe H Me NHCOCF3 H H NHCOCF 3 H Me SCF 3 H H SCF3 H Me SCHF 2 H H SCHF 2 H Me SCH 2 F H H SCH 2 F H Me Ph H H Ph H Me Me 3 Si H H Me 3 Si H Me I Me H I Me Me OCHF 2 Me H OCHF 2 Me Me OCH 2 F Me H OCH 2 F Me Me OCF 2 Cl Me H OCF 2 Cl Me Me OCH 2 CF 3 Me H OCH 2 CF 3 Me Me Et Me H Et Me Me CN Me H CN Me Me NH 2 Me H NH 2 Me Me NHCOMe Me H NHCOMe Me Me NHCOCF3 Me H NHCOCF3 Me Me SCF 3 Me H SCF 3 Me Me SCHF 2 Me H SCHF 2 Me Me SCH 2 F Me H SCH 2 F Me Me Ph Me H Ph Me Me Me 3 Si Me H Me 3 Si Me Me Formulation/Utility Compounds of this invention will generally be used as a formulation or composition with an agriculturally suitable carrier comprising at least one of a liquid diluent, a solid diluent or a surfactant. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as soil type, moisture and temperature. Useful formulations include liquids such as solutions (including emulsifiable concentrates), suspensions, emulsions (including micro emulsions and/or suspoemulsions) and the like which optionally can be thickened into gels. Useful formulations further include solids such as dusts, powders, granules, pellets, tablets, films, and the like which can be water-dispersible ("wettable") or water-soluble. Active ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or "overcoated"). Encapsulation can control or delay release of the active ingredient. Sprayable formulations can be extended in suitable media and used at spray volumes from about one to several hundred liters per hectare. High-strength compositions are primarily used as intermediates for further formulation. The formulations will typically contain effective amounts (e.g. from 0.01-99.99 weight percent) of active ingredient together with diluent and/or surfactant within the following approximate ranges which add up to 100 percent by weight. Weight Percent Active Ingredient Diluent Surfactant Water-Dispersible and Water-soluble 5-90 0-94 1-15 Granules, Tablets and Powders. Suspensions, Emulsions, Solutions 5-50 40-95 0-25 (including Emulsifiable Concentrates and Suspension Concentrates) Dusts 1-25 70-99 0-5 Granules and Pellets 0.01-99 5-99.99 0-15 High Strength Compositions 90-99 0-10 0-2 Typical solid diluents are described in Watkins, et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Dorland Books, Caldwell, New Jersey. Typical liquid diluents are described in Marsden, Solvents Guide, 2nd Ed., Interscience, New York, 1950. McCutcheon 's Detergents and Emulsifϊers Annual, Allured Publ. Corp., Ridgewood, New Jersey, as well as Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964, list surfactants and recommended uses. All formulations can contain minor amounts of additives to reduce foam, caking, corrosion, microbiological growth and the like, or thickeners to increase viscosity. Surfactants include, for example, polyethoxylated alcohols, polyethoxylated alkylphenols, polyethoxylated sorbitan fatty acid esters, dialkyl sulfosuccinates, alkyl sulfates, alkylbenzene sulfonates, organosilicones, N,N-dialkyltaurates, Ugnin sulfonates, naphthalene sulfonate formaldehyde condensates, polycarboxylates, and polyoxyethylene/polyoxypropylene block copolymers. Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, starch, sugar, silica, talc, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Liquid diluents include, for example, water, N,N-dimethylformamide, dimethyl sulfoxide, N-alkylpyrrolidone, ethylene glycol, polypropylene glycol, paraffins, alkylbenzenes, alkylnaphthalenes, oils of olive, castor, linseed, tung, sesame, corn, peanut, cotton-seed, soybean, rape-seed and coconut, fatty acid esters, ketones such as cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, and alcohols such as methanol, cyclohexanol, decanol and tetrahydrofurfuryl alcohol. Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. Dusts and powders can be prepared by blending and, usually, grmding as in a hammer mill or fluid-energy mill. Suspensions are usually prepared by wet-milling; see, for example, U.S. 3,060,084. Preferred suspension concentrates include those containing, in addition to the active ingredient, from 5 to 20% nonionic surfactant (for example, polyethoxylated fatty alcohols) optionally combined with 50-65% liquid diluents and up to 5% anionic surfactants. Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, "Agglomeration", Chemical Engineering, December 4, 1967, pp 147-48, Perry's Chemical Engineer's Handbook, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and following, and WO 91/13546. Pellets can be prepared as described in U.S. 4,172,714. Water-dispersible and water-soluble granules can be prepared as taught in U.S . 4, 144,050, U.S. 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. 5,180,587, U.S. 5,232,701 and U.S. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. 3,299,566. For further information regarding the art of formulation, see U.S. 3,235,361, Col. 6, line 16 through Col. 7, line 19 and Examples 10-41; U.S. 3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; U.S. 2,891,855, Col. 3, line 66 through Col. 5, line 17 and Examples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons, Inc., New York, 1961, pp 81-96; and Hance et al., Weed Control Handbook, 8th Ed., Blackwell Scientific Publications, Oxford, 1989. In the following Examples, all percentages are by weight and all formulations are prepared in conventional ways. Compound numbers refer to compounds in Index Tables A-D. Example A Wettable Powder Compound 8 65.0% dodecylphenol polyethylene glycol ether 2.0% sodium Hgninsulfonate 4.0% sodium silicoaluminate 6.0% montmorillonite (calcined) 23.0%. Example B Granule Compound 8 10.0% attapulgite granules (low volatile matter, 0.71/0.30 mm; U.S.S. No.25-50 sieves) 90.0%. Example C Extruded Pellet Compound 8 25.0% anhydrous sodium sulfate 10.0% crude calcium ligninsulfonate 5.0% sodium alkylnaphthalenesulfonate 1.0% calcium/magnesium bentonite 59.0%. Example D Emulsifiable Concentrate Compound 8 20.0% blend of oil soluble sulfonates and polyoxyethylene ethers 10.0% isophorone 70.0%. Of note are suspension concentrates comprising 15-25% active ingredient, 10-20% nonionic surfactants, 0-5% anionic surfactants, 0-10% organic diluents, and 45-60% water. Example E Compound 2 20.0% polyethoxylated fatty alcohol nonionic surfactant 15.0% ester derivative of montan wax 3.0% calcium lignosulfonate anionic surfactant 2.0% polyethoxylated/polypropoxylated polyglycol block copolymer surfactant 1.0% propylene glycol diluent 6.4% poly(dimethylsiloxane) antifoam agent 0.6% antimicrobial agent 0.1% water diluent 51.9% The formulation ingredients are mixed together as a syrup, Compound 2 is added and the mixture is homogenized in a blender. The resulting slurry is then wet-milled to form a suspension concentrate. Example F Compound 5 20.0% polyethoxylated fatty alcohol nonionic surfactant 15.0% ester derivative of montan wax 3.0% calcium lignosulfonate anionic surfactant 2.0% polyethoxylated/polypropoxylated polyglycol block copolymer surfactant 1-0% propylene glycol diluent 6.4% poly(dimethylsiloxane) antifoam agent 0.6% antimicrobial agent 0.1% water diluent 51.9% The formulation ingredients are mixed together as a syrup, Compound 5 is added and the mixture is homogenized in a blender. The resulting slurry is then wet-milled to form a suspension concentrate. Example G Compound 8 20.0% polyethoxylated fatty alcohol nonionic surfactant 15.0% ester derivative of montan wax 3.0% calcium lignosulfonate anionic surfactant 2.0% polyethoxylated polypropoxylated polyglycol block copolymer surfactant 1.0% propylene glycol diluent 6.4% poly(dimethylsiloxane) antifoam agent 0.6% antimicrobial agent 0.1% water diluent 51.9% The formulation ingredients are mixed together as a syrup, Compound 8 is added and the mixture is homogenized in a blender. The resulting slurry is then wet-milled to form a suspension concentrate. Example H Compound 28 20.0% polyethoxylated fatty alcohol nonionic surfactant 15.0% ester derivative of montan wax 3.0% calcium lignosulfonate anionic surfactant 2.0% polyethoxylated/polypropoxylated polyglycol block copolymer surfactant 1.0% propylene glycol diluent 6.4% poly(dimethylsiloxane) antifoam agent 0.6% antimicrobial agent 0.1 % water diluent 51.9% The formulation ingredients are mixed together as a syrup, Compound 28 is added and the mixture is homogenized in a blender. The resulting slurry is then wet-milled to form a suspension concentrate. Example I Compound 29 20.0% polyethoxylated fatty alcohol nonionic surfactant 15.0% ester derivative of montan wax 3.0% calcium lignosulfonate anionic surfactant 2.0% polyethoxylated/polypropoxylated polyglycol block copolymer surfactant 1.0% propylene glycol diluent 6.4% poly(dimethylsiloxane) antifoam agent 0.6% antimicrobial agent 0.1% water diluent 51.9% The formulation ingredients are mixed together as a syrup, Compound 29 is added and the mixture is homogenized in a blender. The resulting slurry is then wet-milled to form a suspension concentrate. Example J Compound 30 20.0% polyethoxylated fatty alcohol nonionic surfactant 15.0% ester derivative of montan wax 3.0% calcium lignosulfonate anionic surfactant 2.0% polyethoxylated/polypropoxylated polyglycol block copolymer surfactant 1.0% propylene glycol diluent 6.4% poly(dimethylsiloxane) antifoam agent 0.6% antimicrobial agent 0.1% water diluent 51.9% The formulation ingredients are mixed together as a syrup, Compound 30 is added and the mixture is homogenized in a blender. The resulting slurry is then wet-milled to form a suspension concentrate. Example K Compound 31 20.0% polyethoxylated fatty alcohol nonionic surfactant 15.0% ester derivative of montan wax 3.0% calcium lignosulfonate anionic surfactant 2.0%) polyethoxylated/polypropoxylated polyglycol block copolymer surfactant 1.0% propylene glycol diluent 6.4% poly(dimethylsiloxane) antifoam agent 0.6% antimicrobial agent 0.1% water diluent 51.9% The formulation ingredients are mixed together as a syrup, Compound 31 is added and the mixture is homogenized in a blender. The resulting slurry is then wet-milled to form a suspension concentrate. Example L Compound 35 20.0% polyethoxylated fatty alcohol nonionic surfactant 15.0% ester derivative of montan wax 3.0% calcium lignosulfonate anionic surfactant 2.0% polyethoxylated/polypropoxylated polyglycol block copolymer surfactant 1.0% propylene glycol diluent 6.4% poly(dimethylsiloxane) antifoam agent 0.6% antimicrobial agent 0.1% water diluent 51.9% The formulation ingredients are mixed together as a syrup, Compound 35 is added and the mixture is homogenized in a blender. The resulting slurry is then wet-milled to form a suspension concentrate. Example M Compound 36 20.0% polyethoxylated fatty alcohol nonionic surfactant 15.0% ester derivative of montan wax 3.0% calcium lignosulfonate anionic surfactant 2.0% polyethoxylated/polypropoxylated polyglycol block copolymer surfactant 1.0% propylene glycol diluent 6.4% poly(dimethylsiloxane) antifoam agent 0.6% antimicrobial agent 0.1% water diluent 51.9% The formulation ingredients are mixed together as a syrup, Compound 35 is added and the mixture is homogenized in a blender. The resulting slurry is then wet-milled to form a suspension concentrate. Example N Compound 37 20.0% polyethoxylated fatty alcohol nonionic surfactant 15.0% ester derivative of montan wax 3.0% calcium lignosulfonate anionic surfactant 2.0% polyethoxylated polypropoxylated polyglycol block copolymer surfactant 1.0% propylene glycol diluent 6.4% poly(d nethylsiloxane) antifoam agent 0.6% antimicrobial agent 0.1 % water diluent 51.9% The formulation ingredients are mixed together as a syrup, Compound 35 is added and the mixture is homogenized in a blender. The resulting slurry is then wet-milled to form a suspension concentrate. The compounds of this invention are useful as plant disease control agents. The present invention therefore further comprises a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof to be protected, or to the plant seed or seedling to be protected, an effective amount of a compound of the invention or a fungicidal composition containing said compound. The compounds and compositions of this invention provide control of diseases caused by a broad spectrum of fungal plant pathogens in the Basidiomycete, Ascomycete, Oomycete and Deuteromycete classes. They are effective in controlling a broad spectrum of plant diseases, particularly foliar pathogens of ornamental, vegetable, field, cereal, and fruit crops. These pathogens include Plasmopara viticola, Phytophthora infestans, Peronospora tabacina, Pseudoperonospora cubensis, Pythium aphanidermatum, Alternaria brassicae, Septoria nodorum, Septoria tritici, Cercosporidium personatum, Cercospora arachidicola, Pseudocercosporella herpotrichoides, Cercospora beticola, Botrytis cinerea, Monilinia fructicola, Pyricularia oryzae, Podosphaera leucotricha, Venturia inaequalis, Erysiphe graminis, Uncinula necatur, Puccinia recondita, Puccinia graminis, Hemileia vastatrix, Puccinia striiformis, Puccinia arachidis, Rhizoctonia solani, Sphaerothecafuliginea, Fusarium oxysporum, Verticillium dahliae, Pythium aphanidermatum, Phytophthora megasperma, Sclerotinia sclerotiorum, Sclerotium rolfsii, Erysiphe polygoni, Pyrenophora teres, Gaeumannomyces graminis, Rynchospoήum secalis, Fusarium roseum, Bremia lactucae and other generea and species closely related to these pathogens. Compounds of this invention can also be mixed with one or more other insecticides, fungicides, nematocides, bactericides, acaricides, growth regulators, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants or other biologically active compounds to form a multi-component pesticide giving an even broader spectrum of agricultural protection. Examples of such agricultural protectants with which compounds of this invention can be formulated are: insecticides such as abamectin, acephate, azinphos -methyl, bifenthrin, buprofezin, carbofuran, chlorfenapyr, chlorpyrifos, chlorpyrifos-methyl, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, deltamethrin, diafenthiuron, diazinon, diflubenzuron, dimethoate, esfenvalerate, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flucythrinate, tau-fluvalinate, fonophos, imidacloprid, isofenphos, malathion, metaldehyde, methamidophos, methidathion, methomyl, methoprene, methoxychlor, meώyl 7-chloro-2,5-dihydro-2-[[N-(methoxycarbonyl)-N-[4- (taΕuoromemoxy)phenyl]ammo]carbonyl]mdeno[l,2-e][l,3,4]oxadiazine-4a(3H)- carboxylate (indoxacarb), monocrotophos, oxamyl, parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, rotenone, sulprofos, tebufenozide, tefluthrin, terbufos, tetrachlorvinphos, thiodicarb, tralomethrin, trichlorfon and triflumuron; fungicides such as acibenzolar, azoxystrobin, benomyl, blasticidin-S, Bordeaux mixture (tribasic copper sulfate), bromuconazole, carpropamid (KTU 3616), captafol, captan, carbendazim, chloroneb, chlorothalonil, copper oxychloride, copper salts such as copper sulfate and copper hydroxide, cyazofamid, cymoxanil, cyproconazole, cyprodinil (CGA 219417), (S)-3,5-dichloro-N-(3-chloro-l-e l-l -methyl- 2-oxopropyl)-4- methylbenzamide (RH 7281), diclocymet (S-2900), diclomezine, dicloran, difenoconazole, dimethomorph, diniconazole, diniconazole-M, dodine, edifenphos, epoxiconazole (BAS 480F), famoxadone, fenamidone, fenarimol, fenbuconazole, fencaramid (SZX0722), fenpiclonil, fenpropidin, fenpropimo h, fentin acetate, fentin hydroxide, fluazinam, fludioxonil, flumetover (RPA 403397), fluquinconazole, flusilazole, flutolanil, flutriafol, folpet, fosetyl-aluminum, furalaxyl, furametapyr (S-82658), hexaconazole, ipconazole, iprobenfos, iprodione, isoprothiolane, iprovalicarb, kasugamycin, kresoxim-methyl, mancozeb, maneb, mefenoxam, mepronil, metalaxyl, metconazole, metominostrobin/fenomin o strobin (SSF-126), myclobutanil, neo-asozin (ferric methanearsonate), oxadixyl, penconazole, pencycuron, probenazole, prochloraz, propamocarb, propiconazole, propineb, pyrclostrobin, pyrifenox, pyrimethanil, pyroquilon, quinoxyfen, spiroxamine, sulfur, tebuconazole, tetraconazole, thiabendazole, thifluzamide, thiophanate-methyl, thiram, triadimefon, triadimenol, tricyclazole, trifloxystrobin, triticonazole, validamycin, vinclozolin, zineb and zoxamid; nematocides such as aldoxycarb and fenamiphos; bactericides such as streptomycin; acaricides such as amitraz, chinomethionat, chlorobenzilate, cyhexatin, dicofol, dienochlor, etoxazole, fenazaquin, fenbutatin oxide, fenpropathrin, fenpyroximate, hexythiazox, propargite, pyridaben and tebufenpyrad; and biological agents such as Bacillus thuringiensis, Bacillus thuringiensis delta endotoxin, baculovirus, and entomopathogenic bacteria, virus and fungi. The weight ratios of these various mixing partners to compounds of this invention typically are between 100:1 and 1:100, preferably between 30:1 and 1:30, more preferably between 10:1 and l:10 and most preferably between 4: 1 and 1 :4. Of note are combinations with other fungicides giving an even broader spectrum of agricultural protection including azoxystrobin, kresoxim-methyl, pyrclostrobin, trifloxystrobin, benomyl, carbendazim, chlorothalonil, dimethomorph, folpet, mancozeb, maneb, quinoxyfen, validamycin, vinclozolin, fenpropidine, fenpropimorph, bromuconazole, cyproconazole, difenoconazole, epoxyconazole, flusilazole, ipconazole, metconazole, propiconazole, tebuconazole and triticonazole. Of note are combinations with other fungicides of a different mode of action (e.g. mitochondrial respiration inhibition, inhibition of protein synthesis by interference of the synthesis of ribosomal RNA or inhibition of beta-tubulin synthesis) that can be particularly advantageous for resistance management. Examples include combinations of compounds of Formula I and or Formula II (e.g. Compound 8) with azoxystrobin, kresoxim-methyl, pyrclostrobin, trifloxystrobin, carbendazim, famoxadone, fenamidone, benomyl, cymoxanil, dimethomorph, folpet, fosetyl-aluminum, metalaxyl, mancozeb, maneb. These combinations can be particularly advantageous for resistance management, especially where the fungicides of the combination control the same or similar diseases. Of note are combinations with other fungicides for controlling grape diseases including dithiocarbamates such as mancozeb, maneb, propineb and zineb, phthalimids such as folpet, copper salts such as copper sulfate and copper hydroxide, strobilurins such as azoxystrobin, pyrclostrobin and trifloxystrobin, , phenylamides such as metalaxyl, phosphonates such as fosetyl-Al, morpholines such as dimethomorph, and other fungicides such as cymoxanil, famoxadone and fenamidone. Of note are combinations with other fungicides for controlling potato diseases including dithiocarbamates such as mancozeb, maneb, propineb and zineb, copper salts such as copper sulfate and copper hydroxide, strobilurins such as pyrclostrobin and trifloxystrobin, phenylamides such as metalaxyl, carbamates such as propamocarb, phenylpyriylamines such as fluazinam, morpholines such as dimethomorph, and other fungicides such as chlorothalonil, cyazofamid, cymoxanil, famoxadone, fenamidone, zoxamid and iprovalicarb. Of particular note are combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with azoxystrobin, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with kresoxim-methyl, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with pyrclostrobin, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with trifloxystrobin, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31 , Compound 35, Compound 36 or Compound 37 with carbendazim, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with chlorothalonil, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with dimethomorph, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with folpet, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31 , Compound 35, Compound 36 or Compound 37 with mancozeb, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with maneb, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with quinoxyfen, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with validamycin, combinations of Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with vinclozolin, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with fenpropidine, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with fenpropimorph, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with bromuconazole, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with cyproconazole, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with difenoconazole, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with epoxyconazole, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with flusilazole, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with ipconazole, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with metconazole, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with propiconazole, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31 , Compound 35, Compound 36 or Compound 37 with tebuconazole, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with triticonazole, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with famoxadone, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with fenamidone, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31 , Compound 35, Compound 36 or Compound 37 with benomyl, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with cymoxanil, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with dimethomorph, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with folpet, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with fosetyl-aluminum, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with metalaxyl, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with propineb, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with zineb, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with copper sulfate, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with copper hydroxide, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with propamocarb, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with cyazofamid, Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31 , Compound 35, Compound 36 or Compound 37 with zoxamid and Compound 2, Compound 5, Compound 8, Compound 28, Compound 29, Compound 30, Compound 31, Compound 35, Compound 36 or Compound 37 with iprovalicarb. Plant disease control is ordinarily accomplished by applying an effective amount of a compound of this invention either pre- or post-infection, to the portion of the plant to be protected such as the roots, stems, foliage, fruit, seeds, tubers or bulbs, or to the media (soil or sand) in which the plants to be protected are growing. The compounds can also be applied to the seed to protect the seed and seedling. Rates of application for these compounds can be influenced by many factors of the environment and should be determined under actual use conditions. Foliage can normally be protected when treated at a rate of from less than 1 g/ha to 5,000 g/ha of active ingredient. Seed and seedlings can normally be protected when seed is treated at a rate of from 0.1 to 10 g per kilogram of seed. The following TESTS demonstrate the control efficacy of compounds of this invention on specific pathogens. The pathogen control protection afforded by the compounds is not limited, however, to these species. See Index Tables A-E for compound descriptions. The following abbreviations are used in the Index Tables that follow: Me is methyl, Et is ethyl, Ph is phenyl, OMe is methoxy, OEt is ethoxy. The abbreviation "dec" indicates that the compound appeared to decompose on melting. The abbreviation "Ex." stands for "Example" and is followed by a number indicating in which example the compound is prepared. INDEX TABLE A Compound Number (R 5 )m (R 6 )P m.p. (°C.) 1 3-C1-5-CF3 3-Cl 108-109 2 3-CI-5-CF3 3-Cl-5-Me 3 3-CI-5-CF3 3-OH INDEX TABLE B INDEX TART ,F. f! Compound Number (R 5 ) H (R 6 )r m.p. (°C.) 32 6-C1 2-Me 105-106 33 6-OC 6 H 4 (3-CF ) 2-Me 90-91 INDEX TABLE D 34 3-CI-5-CF3 2-Cl-6-OMe 35 3-CI-5-CF3 3,5-Cl 2 *See Index Table E for l E NMR data. INDEX TABLE E Cmpd No. l E NMR Data (3 OOmHz; CDCI3 solution unless indicated otherwise) 1 5 δ 4.95 (ιn,2H), 7.44 (m,lH), 8.0 (s,lH), 8.2-8.3 (m,2H), 8.5 (tn,lH), 8.8 (m,lH) 7 (DMSO-d 6 ) δ 4.8 (m,2H), 8.54 (s,lH), 8.55 (s, IH), 8.84 (s,lH), 8.9 (s,lH), 9.5 (bs,lH) 8 δ 2.57 (s,3H), 4.96 ( ,2H), 7.22 (s,lH), 7.48 (bs, IH), 8.00 (s,lH), 8.71 (s,lH) 18 δ 4.95 (m,2H), 7.76 (m,lH), 7.94 (bs,lH), 8.00 (s,lH), 8.16 (m,lH), 8.74 (s,lH) 19 (OMSO-d 6 ) δ 2.30 (s, 3H), 4.8 (m,2H), 6.3 (m,lH), 8.2 (m,lH), 8.47 (s,lH), 8.93 (s,lH), 10.4 (m,lH), 12.4 (bs,lH) 20 δ 2.80 (s, 3H), 4.94 (m,2H), 7.4 (bs,lH), 7.6 (m, IH), 8.0 (m,2H), 8.73 (s,lH) 21 δ 2.80 (s, 3H), 4.95 (m,2H), 7.4 (bs,lH), 7.6 (m, IH), 8.0 (m,2H), 8.72 (s,lH) 22 δ 4.97 (ιn,2H), 7.44 (m,lH), 7.99 (s,lH), 8.71 (m,lH), 8.80 (s,lH), 9.42 (bs,lH) 23 δ 3.50 (s, 3H), 4.87, (s,2H), 4.98 (m,2H), 7.79 (m,lH), 7.98 (S,1H), 8.38 (m,lH), 8.74 (s,lH), 8.88 (bs,lH) 24 δ 4.70 (m,2H), 7.0 (bs,lH), 7.3-4 (ιn,3H), 7.7-7.8 (m,3H), 7.9 (s,lH), 8.25 (m,lH), 8.4 ( S ,1H) 25 δ 2.73 (s, 3H), 4.91 (ιn,2H), 7.25 (m,lH), 7.4 (bs, IH), 7.8 (ιn,lH), 8.00 (s,lH), 8.73 (s,lH) 26 δ 4.94 (m,2H), 7.80 (m,lH), 7.9 (bs, IH), 8.0 (s,lH), 8.40 (m,lH), 8.77 (s,lH), 9.22 (s,lH) 27 (DMSO-rf 6 ) δ 4.8 (m,2H), 7.0 (m,lH), 7.3(m,lH), 7.3 (m,lH), 7.5 (m,lH), 7.8 (m,lH), 8.3 (m,2H), 8.4 (m,lH), 8.5 (s,lH), 8.9 (s,lH), 9.5 (m,lH) 30 δ 1.62 (d,3H, J is 6.7 Hz), 5.84 (m,lH), 7.35 (d,lH,J is 5.2 Hz), 7.40 (d,lH,J is 6.9 Hz), 7.99 (d,lH,J is 1.8 Hz), 8.34 (d,lH,J is 5.2 Hz), 8.70 (s,lH) 34 δ 4.00 (s, 3H), 4.88, (m,2H), 7.09 (s,lH), 7.33 (m, IH), 7.80 (bs,lH), 8.00 (s,lH), 8.78 (s,lH) 35 δ 4.98 (d,2H,J is 3.8), 7.5 (bs,lH), 8.00 (s,lH), 8.58 (s,2H), 8.71(s,lH). 36 δ 1.58(d,3H, J is 6.6Hz), 5.7-5.8(m, IH), 7.4(m,2H), 7.77(m, IH), 8.35(m, IH), 8.40(m,lH). 37 δ 1.59(d,3H, J is 6.6 Hz), 5.75(m,lH), 7.3(bs,lH), 7.34(d,lH, J is 5.2 Hz), 7.91(d,lH, J is 1.9 Hz), 8.33(d,lH, J is 5.4 Hz), 8.49(d,lH, Jis 1.9 Hz). 38 δ 1.62 (d, 3H,J is 6.7 Hz), 5.48 (m,l H), 7.35(d,l H,J is 5.2 Hz), 7.40(d,l H,J is 6.9), 7.99(d,l H,J is 1.8 Hz), 8.34(d,l H,J is 5.2), 8.70(s,l H). a *H NMR data are in ppm downfield from tetramethylsilane. Couplings are designated by (s)-singlet, (d)-doublet, (t)-triplet, (q)-quartet, (m)-multiplet, (dd)-doublet of doublets, (dt)-doublet of triplets, (br s)-broad singlet. BIOLOGICAL EXAMPLES OF THE INVENTION General protocol for preparing test suspensions: Test compounds are first dissolved in acetone in an amount equal to 3% of the final volume and then suspended at the desired concentration (in ppm) in acetone and purified water (50/50 mix) containing 250 ppm of the surfactant Trem® 014 (polyhydric alcohol esters). The resulting test suspensions are then used in the following tests. Spraying a 200 ppm test suspension to the point of run-off on the test plants is the equivalent of a rate of 500 g/ha. TEST A The test suspension was sprayed to the point of run-off on wheat seedlings. The following day the seedlings were inoculated with a spore dust of Erysiphe graminis f. sp. tritici, (the causal agent of wheat powdery mildew) and incubated in a growth chamber at 20°C for 7 days, after which disease ratings were made. TEST B The test suspension was sprayed to the point of run-off on wheat seedlings. The following day the seedlings were inoculated with a spore suspension of Puccinia recondita (the causal agent of wheat leaf rust) and incubated in a saturated atmosphere at 20°C for 24 h, and then moved to a growth chamber at 20°C for 6 days, after which disease ratings were made. TEST C The test suspension was sprayed to the point of run-off on rice seedlings. The following day the seedlings were inoculated with a spore suspension of Pyricularia oryzae (the causal agent of rice blast) and incubated in a saturated atmosphere at 27°C for 24 h, and then moved to a growth chamber at 30°C for 5 days, after which disease ratings were made. TEST D The test suspension was sprayed to the point of run-off on tomato seedlings. The following day the seedlings were inoculated with a spore suspension of Phytophthora infestans (the causal agent of potato and tomato late blight) and incubated in a saturated atmosphere at 20°C for 24 h, and then moved to a growth chamber at 20°C for 5 days, after which disease ratings were made. TEST E The test suspension was sprayed to the point of run-off on grape seedlings. The following day the seedlings were inoculated with a spore suspension of Plasmopara viticola (the causal agent of grape downy mildew) and incubated in a saturated atmosphere at 20°C for 24 h, moved to a growth chamber at 20°C for 6 days, and then incubated in a saturated atmosphere at 20°C for 24 h, after which disease ratings were made. TEST F Tomato (or potato) seedlings are inoculated with a spore suspension of Phytophthora infestans (the causal agent of potato and tomato late blight) and incubated in a saturated atmosphere at 20°C for 24 h. The next day, test suspension is sprayed to the point of run-off and the treated plants are moved to a growth chamber at 20°C for 5 days, after which disease ratings are made. TEST G Grape seedlings are inoculated with a spore suspension of Plasmopara viticola (the causal agent of grape downy mildew) and incubated in a saturated atmosphere at 20°C for 24 h. The next day, test suspension is sprayed to the point of run-off and the treated plants are moved to a growth chamber at 20°C for 6 days, and then incubated in a saturated atmosphere at 20° C for 24 h, after which disease ratings are made. Results for Tests A-E are given in Table A. In the table, a rating of 100 indicates 100% disease control and a rating of 0 indicates no disease control (relative to the controls). A dash (-) indicates no test results. ND indicates disease control not determined due to phyto toxicity. In addition to the Tests shown below, compounds of this invention (e.g. compounds 2, 5, 8, 28, 29, 30, 31, 35, 36 and 37) are considered to have significant curative utility, especially for grape downy mildew. Table A CmpdNo. Test A TestB Test C TestD TestE Tes F Test G 1 0 0 0 90 29 2 0 ND - 100 - 99 21 28 7 - - 99 - 19 98 99 0 0 19 0 0 0 8 - 100 100 0 28 0 7 0 0 9 74 16 0 0 9 0 7 8 0 19 0 7 24 0 9 0 3 23 0 19 90 100 98 0 38 30 7 8 0 9 100 34 8 13 0 0 25 0 0 9 80 32 0 0 9 0 7 8 0 28 87 25 8 69 68 88 16 8 0 0 0 7 0 72 9 7 32 8 0 0 7 25 8 0 9 13 79 16 0 32 0 25 0 0 0 0 32 16 - - 0 100 100 97# 37* - - 0 100 100 100* - - 0 100 100 100* - - 0 100 100 100** 0 0 0 32 - 91 - - 71 - 0 44 - 31 - 0 30 - 100 100 100* 0 38 0 100 100 100 0 19 0 100 100 100 - - _ - 69* 0** ' tato seedlings * 100 ppm. ** 20 ppm.

Claims: CLAIMS What is claimed is: 1. A compound selected from Formula I and Formula II, N-oxides and agriculturally suitable salts thereof, wherein: A is a substituted pyridinyl ring; B is a substituted pyridinyl ring; W is C=L or SO n ; L is O or S; R 1 and R 2 are each independently H; or Cj-Cg alkyl, C 2 -Cg alkenyl, C 2 -C β alkynyl or C3-C6 cycloalkyl, each optionally substituted; R 3 is H; or C^Cg alkyl, C -Cg alkenyl, C 2 -C 6 alkynyl or C3-C6 cycloalkyl, C 2 -C 6 alkylcarbonyl, C 2 -Cg alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl or C3-C8 dialkylaminocarbonyl; R 4 is Cj-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -Cg alkynyl or C 3 -C 6 cycloalkyl, each optionally substituted; X is O or S; and n is 1 or 2; provided that when W is C=O and R 1 , R 2 and R 3 are H; then B is other than 4-trifluoromethyl-3 -pyridinyl, 2-chloro-4-pyridinyl and 2,6-dihalo-4-pyridinyl. 2. A compound of Claim 1 wherein A is a pyridinyl ring substituted with from 1 to 4 R 5 ; B is a pyridinyl ring substituted with from 1 to 4 R 6 ; R 1 and R 2 are each independently H; or Cj-Cg alkyl, C 2 -C6 alkenyl, C -C 6 alkynyl or C 3 -Cg cycloalkyl, each optionally substituted with one or more substituents selected from the group consisting of halogen, CΝ, ΝO 2 , hydroxy, C j -04 alkoxy, Cj-C-4 alkylthio, C r C 4 alkylsulfinyl, C r C 4 alkylsulfonyl, C 2 -C 4 alkoxycarbonyl, C r C alkylamino, C 2 -C 8 dialkylamino and C 3 -C 6 cycloalkylamino; R 4 is C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C^ alkynyl or C 3 -C 6 cycloalkyl, each optionally substituted with one or more substituents selected from the group consisting of halogen, CN, NO 2 , hydroxy, C r C 4 alkoxy, C r C 4 alkylthio, C r C 4 alkylsulfinyl, Cι-C 4 alkylsulfonyl, C 2 -C 4 alkoxycarbonyl, Cι-C 4 alkylamino, C 2 -Cg dialkylamino and C3-C6 cycloalkylamino; R 5 and R 6 are each independently Cj -Cg alkyl, C 2 -Cg alkenyl, C 2 -Cg alkynyl, C 3 -C 6 cycloalkyl, C^ ~C haloalkyl, C 2 -Cg haloalkenyl, C 2 -C6 haloalkynyl, C 3 -C6 halocycloalkyl, halogen, CN, CO 2 H, CONH 2 , NO 2 , hydroxy, C1-C 4 alkoxy, C ! -C 4 haloalkoxy, C1-C4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C4 alkylsulfonyl, Ci -C 4 haloalkylthio, C2-C4 haloalkylsulfinyl, C1-C 4 haloalkylsulfonyl, C1-C 4 alkoxycarbonyl, C1-C alkylamino, C 2 -Cg dialkylamino, C 3 -C6 cycloalkylamino, C 2 -Cg alkylcarbonyl, C 2 -Cg alkoxycarbonyl, C 2 -Cg a ylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl, C3-C 6 trialkylsilyl; or R 5 and R 6 are each independently phenyl, benzyl or phenoxy, each optionally substituted with C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C4 alkynyl, C 3 -C6 cycloalkyl, C 1 -C 4 haloalkyl, C 2 -C 4 haloalkenyl, C2-C4 haloalkynyl, C 3 -C6 halocycloalkyl, halogen, CN, NO 2 , C1-C4 alkoxy, C 1 -C4 haloalkoxy, Ci -C 4 alkylthio, C1-C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl C 1 -C 4 alkoxycarbonyl, C 1 -C 4 alkylamino, C 2 -Cg dialkylamino, C3-C5 cycloalkylamino, C 3 -C 6 (alkyl)cycloalkylamino, C 2 -C 4 alkylcarbonyl, C 2 -Cg alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl, C 3 ~C dialkylaminocarbonyl or C 3 -C 6 trialkylsilyl. 3. A compound of Claim 2 of Formula I wherein W is C=O. 4. A compound of Claim 3 wherein A is a substituted 3-pyridinyl ring. 5. A compound of Claim 3 wherein A is a 2-pyridinyl ring substituted with from 1 to 4 R 5 ; and B is substituted with from 1 to 4 R 6 , with at least one R 6 located in a position ortho to the link with W. 6. A compound of Claim 5 wherein B is either a 3-pyridinyl ring or 4-pyridinyl ring having an R 6 at each position ortho to the link with W and optionally 1 to 2 additional R 6 . 7. A compound of Claim 6 wherein each R 6 is either halogen or methyl. 8. A compound of Claim 7 wherein B is a 3-pyridinyl ring wherein one R 6 is Cl and is located at the 2-position ortho to the link with W, another R 6 is selected from Cl or methyl and is located at the 4-position ortho to the link with W and a third optional R 6 is methyl at the 6-position. 9. The compound of Claim 8 wherein A is 3 -chloro-5-CF 3 -2-pyridinyl. 10. The compound of Claim 5 or Claim 7 wherein R 1 is H and R 2 is CH . 11. The compound of Claim 2 selected from the group consisting of 2,4-Dichloro-N-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]methyl]-3- pyridinecarboxamide, 2,4-DicMoro-N-[l-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl]-3- pyridinecarboxamide, 2,4-DicMoro-N-[[3-chloro-5-(trifluorome yl)-2-pyridinyl]methyl]-6-methyl-3- pyridinecarboxamide, and 2,4-DicMoro-N-[l-[3-chloro-5-( fluoromemyl)72-pyridinyl]ethyl]-6-methyl-3- pyridinecarboxamide. 12. A compound of Claim 2 of Formula II wherein A is a 2-pyridinyl ring substituted with from 1 to 4 R 5 ; and B is substituted with from 1 to 4 R 6 , with at least one R 6 located in a position ortho to the link with the carbon that is bonded to both X and B. 13. A compound of Claim 12 wherein X is S . 14. A compound of Claim 2 of Formula I wherein each R 5 is independently C^-Cg alkyl, C 2 -Cg alkenyl, C 2 -Cg alkynyl, C3-C 6 cycloalkyl, C1-C6 haloalkyl, C 2 -Cg haloalkenyl, C 2 -Cg haloalkynyl, C 3 -C6 halocycloalkyl, halogen, CΝ, CO 2 H, COΝH 2 , NO 2 , hydroxy, C r C 4 alkoxy, C 1 -C haloalkoxy, C^C^ alkylthio, C1-C4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, Cj-C haloalkylthio, C \ -C 4 haloalkylsulfinyl, Ci -C 4 haloalkylsulfonyl, C 1 -C4 alkoxycarbonyl, C 1 -C 4 alkylamino, C 2 -Cg dialkylamino, C 3 -C 6 cycloalkylamino, C 2 -C 6 alkylcarbonyl, C 2 -C alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl, C 3 -C dialkylaminocarbonyl, C3-C 6 trialkylsilyl; provided that when A is 2-pyridinyl, then R 5 is other than Ci to Cg haloalkyl; and each R 6 is independently C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, Cj-Cg haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, CN, CO 2 H, CONH 2 , NO 2 , hydroxy, C r C 4 alkoxy, C J -C4 haloalkoxy, C j -0 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, 0^04 haloalkylthio, C 1 -C 4 haloalkylsulfinyl, C 1 -C4 haloalkylsulfonyl, C1-C 4 alkoxycarbonyl, C1-C 4 alkylamino, C 2 -Cg dialkylamino, C 3 -C 6 cycloalkylamino, C -C6 alkylcarbonyl, C -Cg alkoxycarbonyl, C 2 -C6 alkylaminocarbonyl, C -C dialkylaminocarbonyl, C 3 -C6 trialkylsilyl; or R 5 and R 6 are each independently phenyl, benzyl or phenoxy, each optionally substituted with ^-0 4 alkyl, C 2 -C4 alkenyl, C 2 -C 4 alkynyl, C 3 -C 6 cycloalkyl, Cγ -C 4 haloalkyl, C 2 -C haloalkenyl, C 2 -C 4 haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, CN, NO 2 , Cχ-C 4 alkoxy, C r C 4 haloalkoxy, C r C 4 alkylthio, C r C 4 alkylsulfinyl, C ! -C alkylsulfonyl Cι-C alkoxycarbonyl, C1-C 4 a&ylamino, C 2 -C 8 dialkylamino, C -C 6 cycloalkylamino, C -C 6 (alkyl)cycloalkylamino, C 2 -C 4 alkylcarbonyl, C 2 -C 6 alkoxycarbonyl, C 2 -C 6 alkylaminocarbonyl, C -C 8 dialkylaminocarbonyl or C 3 -C 6 trialkylsilyl. 15. A compound of Claim 14 wherein W is C=O; each R 5 is independently C r C 6 alkyl, C 2 -Cg alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, Cι-C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C 3 -C 6 halocycloalkyl, halogen, CN, CO 2 H, CONH 2 , NO 2 , hydroxy, C r C 4 alkoxy, Cj-C4 haloalkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C 1 -C4 alkylsulfonyl, C 1 -C4 haloalkylthio, C j -C haloalkylsulfinyl, C j -C 4 haloalkylsulfonyl, C j -C alkoxycarbonyl, C1-C4 alkylamino, C 2 -Cg dialkylamino, C3-C6 cycloalkylamino, C -C 6 alkylcarbonyl, C -Cg alkoxycarbonyl, C 2 -Cg alkylaminocarbonyl, C 3 -Cg dialkylaminocarbonyl, C3-C6 trialkylsilyl; provided that when A is 2-pyridinyl, then R 5 is other than C^ to Cg haloalkyl. 16. A compound of Claim 15 wherein R 5 is Cl, Br, CH 3 , OCF 3 , OCHF 2 , OCH 2 CF 3 , OCF 2 CF 3 , OCF 2 CF 2 H, OCHFCF3, SCF 3 , SCHF 2 , SCH 2 CF 3 , SCF 2 CF 3 , SCF 2 CF 2 H, SCHFCF3, SOCF3, SOCHF 2 , SOCH 2 CF 3 , SOCF 2 CF 3 , SOCF 2 CF 2 H, SOCHFCF3, SO 2 CF 3 , SO 2 CHF 2 , SO 2 CH 2 CF 3 , SO 2 CF 2 CF 3 , SO 2 CF 2 CF 2 H or SO 2 CHFCF 3 . 17. The compound of Claim 16 selected from the group consisting of 2,4-Dichloro-N-[(3,5-dichloro-2-pyridinyl)methyl]-3-pyridinecarboxamide, 2,4-Dichloro-N-[l-(3,5-dichloro-2-pyridinyl)ethyl]-3-pyridinecarboxamide, 2,4-Dichloro-N- [(3 , 5 -dichloro-2-pyridinyl)methyl] -6-methyl-3 - pyridinecarboxamide, 2,4-Dichloro-N- [ 1 -(3 ,5 -dichloro-2-pyridinyl)ethyl] -6-methyl-3 - pyridinecarboxamide, N-[(5-bromo-3-chloro-2-pyridinyl)methyl]-2,4-dichloro-3-pyridinecarboxamide, N-[l-(5-bromo-3-chloro-2-pyridinyl)ethyl]-2,4-dichloro-3-pyridinecarboxamide, N-[(5-bromo-3-chloro-2-pyridinyl)methyl]-2,4-dichloro-6-methyl-3- pyridinecarboxamide, and N-[l-(5-bromo-3-chloro-2-pyridinyl)ethyl]-2,4-dichloro-6-methyl-3- pyridinecarboxamide. 18. A fungicidal composition comprising a fungicidally effective amount of a compound of Claim 1 and at least one additional component selected from the group consisting of surfactants, solid diluents or liquid diluents. 19. A fungicidal composition comprising a mixture of a compound of Claim 1 and at least one other fungicide having a different mode of action. 20. A method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed or seedling, a fungicidally effective amount of a compound of Claim 1.

Inventors: NEUBERT TIMOTHY DONALD, PIOTROWSKI DAVID WALTER, WALKER MICHAEL PAUL, NEUBERT, TIMOTHY, DONALD, PIOTROWSKI, DAVID, WALTER, WALKER, MICHAEL, PAUL
Applicants: DU PONT, NEUBERT TIMOTHY DONALD, PIOTROWSKI DAVID WALTER, WALKER MICHAEL PAUL, E. I. DU PONT DE NEMOURS AND COMPANY, NEUBERT, TIMOTHY, DONALD, PIOTROWSKI, DAVID, WALTER, WALKER, MICHAEL, PAUL
Application year: 2001
Main classification: C07D213
IPC codes: A01N43, C07D213